Publications: Prof Chloe Orkin
Ring K, Orkin C
(
2024
)
.
Long-acting antiretroviral therapy in the context of viral suppression
.
Current Opinion in HIV and AIDS
vol.
20
,
(
1
)
4
-
10
.
Orkin C, Paparini S, Hayes R
(
2024
)
.
Perspectives of people with HIV on implementing long acting cabotegravir plus rilpivirine in clinics and community settings in the UK: results from the anti-sexist, anti-racist, anti-ageist ILANA study
.
Clinical Infectious Diseases
Palumbo L, Picchio CA, Barbier F, Calderon-Cifuentes A, James J, Lunchenkov N, Nutland W, Owen G et al.
(
2024
)
.
Co-creating a Mpox Elimination Campaign in the WHO European Region: The Central Role of Affected Communities
.
Open Forum Infectious Diseases
vol.
11
,
(
10
)
Jackson SS, O’Callaghan S, Ward E, Orkin CM, Clarke MA, Berner AM
(
2024
)
.
Rationale and design of the Self-TI Study protocol: a cross-sectional human papillomavirus self-testing pilot study among transgender adults in England
.
BMJ Open
vol.
14
,
(
7
)
Paparini S, Whelan I, Mwendera C, Hayes R, Maatouk I, Lewis R, Nunez MP, Mozalevskis A et al.
(
2024
)
.
Prevention of sexual transmission of mpox: a systematic review and qualitative evidence synthesis of approaches
.
Infectious Diseases
vol.
56
,
(
8
)
589
-
605
.
McCabe L, Burns JE, Latifoltojar A, Post FA, Fox J, Pool E, Waters A, Santana B et al.
(
2024
)
.
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV
.
AIDS
vol.
38
,
(
10
)
1513
-
1522
.
Ring K, Smuk M, Shongwe M, Okonta L, Mackie NE, Ayres S, Barber TJ, Akodu J et al.
(
2024
)
.
Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)
.
HIV Medicine
vol.
25
,
(
10
)
1125
-
1134
.
Saloniki E-C, Halvorsrud K, Whelan I, Halim N, George R, Orkin C
(
2024
)
.
Staff disability data in UK higher education: Evidence from EDI reports
.
Medical Humanities
vol.
50
,
(
3
)
555
-
560
.
Orkin C, Ring K
(
2024
)
.
Implementing long-acting injectable cabotegravir and rilpivirine in Africa
.
The Lancet Infectious Diseases
vol.
24
,
(
10
)
1060
-
1061
.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C et al.
(
2024
)
.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
.
The Lancet HIV
vol.
11
,
(
3
)
e156
-
e166
.
Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina J-M, Lazzarin A, Maggiolo F et al.
(
2024
)
.
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy
.
AIDS
vol.
38
,
(
7
)
983
-
991
.
Paton NI, Stöhr W, Arenas-Pinto A, Clarke A, Williams I, Johnson M, Orkin C, Chen F et al.
(
2024
)
.
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
.
EClinicalMedicine
vol.
69
,
Hayes R, Dakin F, Smuk M, Paparini S, Apea V, Dewsnap C, Waters L, Anderson J et al.
(
2024
)
.
Cross-sectional survey of sexual health professionals’ experiences and perceptions of the 2022 mpox outbreak in the UK
.
BMJ Open
vol.
14
,
(
1
)
Orkin C
(
2024
)
.
Should Human Immunodeficiency Virus Testing Be Replaced With Combined Blood-Borne Virus Testing?
.
Open Forum Infectious Diseases
vol.
11
,
(
2
)
Howe A, Orkin C, Apea V
(
2023
)
.
The under-representation of racially minoritised doctors in academic general practice training
.
BJGP Open
vol.
8
,
(
2
)
Orkin C, Molina J-M, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H et al.
(
2023
)
.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
.
The Lancet HIV
vol.
11
,
(
2
)
e75
-
e85
.
Guaraldi G, Milic J, Cascio M, Mussini C, Martinez E, Levin J, Calzavara D, Mbewe R et al.
(
2023
)
.
Ageism: the -ism affecting the lives of older people living with HIV
.
The Lancet HIV
vol.
11
,
(
1
)
e52
-
e59
.
Howe A, Wan YI, Gilleece Y, Aebi-Popp K, Dhairyawan R, Bhagani S, Paparini S, Orkin C
(
2023
)
.
Gender and ethnicity intersect to reduce participation at a large European hybrid HIV conference
.
BMJ Leader
vol.
8
,
(
3
)
227
-
233
.
Mitjà O, Paredes R, Cabtree B, Orkin C
(
2023
)
.
Classifying necrotising mpox as an AIDS-defining condition
.
The Lancet
vol.
402
,
(
10414
)
1751
-
1752
.
Wan YI, Smuk M, Pearse RM, Paparini S, Apea VJ, Orkin CM
(
2023
)
.
Clinical research in the NHS: a cross-sectional study of research engagement during the monkeypox pandemic
.
BMJ Leader
vol.
7
,
(
Suppl 2
)
Cevik M, Orkin C
(
2023
)
.
Changing face of mpox
.
Clinical Microbiology and Infection
vol.
29
,
(
12
)
1485
-
1486
.
Thornhill JP, Gandhi M, Orkin C
(
2023
)
.
Mpox: The Reemergence of an Old Disease and Inequities
.
Annual Review of Medicine
vol.
75
,
(
1
)
159
-
175
.
Shabbir A, Chhetri I, Khambata RS, Parakaw T, Lau C, Aubdool MABN, Massimo G, Dyson N et al.
(
2023
)
.
A double-blind, randomised, placebo-controlled parallel study to investigate the effect of sex and dietary nitrate on COVID-19 vaccine-induced vascular dysfunction in healthy men and women: protocol of the DiNOVasc-COVID-19 study
.
Trials
vol.
24
,
(
1
)
Hazra A, Zucker J, Bell E, Flores J, Gordon L, Mitjà O, Suñer C, Lemaignen A et al.
(
2023
)
.
Mpox in people with past infection or a complete vaccination course: a global case series
.
The Lancet Infectious Diseases
vol.
24
,
(
1
)
57
-
64
.
Henao-Martínez AF, Orkin CM, Titanji BK, Rodriguez-Morales AJ, Salinas JL, Franco-Paredes C, Tuells J, Chastain DB
(
2023
)
.
Hospitalization risk among patients with Mpox infection—a propensity score matched analysis
.
Therapeutic Advances in Infectious Disease
vol.
10
,
Orkin C, Paparini S, Thornhill JP, Apea V, Mwendera CA, Smuk M, Hayes R, Anderson J
(
2023
)
.
SHARING to create knowledge in a crisis
.
BMJ Leader
vol.
7
,
(
Suppl 2
)
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink H-J et al.
(
2023
)
.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
.
Journal of Antimicrobial Chemotherapy
vol.
78
,
(
9
)
2361
-
2365
.
Martinello M, Bhagani S, Shaw D, Orkin C, Cooke G, Gane E, Iser D, Ustianowski A et al.
(
2023
)
.
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study
.
JHEP Reports
vol.
5
,
(
10
)
Bradshaw D, Abramowicz I, Bremner S, Verma S, Gilleece Y, Kirk S, Nelson M, Housman R et al.
(
2023
)
.
Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease
.
PLOS ONE
vol.
18
,
(
7
)
Farooq HZ, Apea V, Kasadha B, Ullah S, Hilton-Smith G, Haley A, Scherzer J, Hand J et al.
(
2023
)
.
Study protocol: the ILANA study – exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK – a qualitative multiphase longitudinal study design
.
BMJ Open
vol.
13
,
(
7
)
Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y et al.
(
2023
)
.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure
.
Clinical Infectious Diseases
.
vol.
77
,
1423
-
1431
.
Orkin C, Paparini S, Apea V
(
2023
)
.
Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK
.
The Lancet HIV
Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, Maggiolo F, Stellbrink H-J et al.
(
2023
)
.
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
.
EClinicalMedicine
vol.
59
,
Dhairyawan R, Milner A, Thornhill JP, Kwardem L, Matin N, Orkin C, Deane K
(
2023
)
.
Experiences of initiating rapid antiretroviral therapy among people newly diagnosed with HIV in East London: a qualitative study
.
Sexually Transmitted Infections
vol.
99
,
(
7
)
455
-
460
.
Mitjà O, Alemany A, Marks M, Mora JIL, Rodríguez-Aldama JC, Silva MST, Herrera EAC, Crabtree-Ramirez B et al.
(
2023
)
.
Mpox in people with advanced HIV infection: a global case series
.
The Lancet
vol.
401
,
(
10380
)
939
-
949
.
Béguelin C, Atkinson A, Boyd A, Falconer K, Kirkby N, Suter‐Riniker F, Günthard HF, Rockstroh JK et al.
(
2023
)
.
Hepatitis delta infection among persons living with HIV in Europe
.
Liver International
vol.
43
,
(
4
)
819
-
828
.
Ramgopal M, Warupa A, Baumgarten A, Berhe M, Pozniak A, Orkin C, Tiraboschi JM, Hagins D et al.
(
2023
)
.
5-year outcomes of bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 cell count in two Phase 3 randomised clinical trials
.
HIV MEDICINE
.
vol.
24
,
33
-
33
.
Orkin C, Koethe JR, Kumar PN, Xu ZJ, Plank RM, Greaves W, Sklar P, Lahoulou R
(
2023
)
.
Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen
.
HIV MEDICINE
.
vol.
24
,
53
-
54
.
Orkin C
(
2023
)
.
Lenacapavir in first-line therapy
.
The Lancet HIV
vol.
10
,
(
1
)
e2
-
e3
.
Sax P, Arribas J, Orkin C, Lazzarin A, Pozniak A, Maggiolo F, Stellbrink H-J, Yazdanpanah Y et al.
(
2023
)
.
Long-term integrated analysis of B/F/TAF in treatment-naive adults with HIV through five years of follow-up
.
HIV MEDICINE
.
vol.
24
,
55
-
56
.
Orkin C, Antinori A, Rockstroh J, Guillen SM, Martorell C, Molina J-M, Lazzarin A, Maggiolo F et al.
(
2023
)
.
Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
.
HIV MEDICINE
.
vol.
24
,
21
-
22
.
Hayes R, Mwendera C, Apea V, Paparini S, Orkin C
(
2023
)
.
What influences acceptability of long-acting injectable ART and treatment setting: preliminary qualitative findings from the ILANA trial
.
HIV MEDICINE
.
vol.
24
,
31
-
32
.
Dimitrakoff J
(
2022
)
.
Monkeypox Virus Infection across 16 Countries - April-June 2022
.
N Engl J Med
vol.
387
,
(
25
)
Dimitrakoff J
(
2022
)
.
Monkeypox Virus Infection across 16 Countries — April–June 2022
.
New England Journal of Medicine
vol.
387
,
(
25
)
Orkin C
(
2022
)
.
Reflections and intersections: disability, ‘ableism’ and metamodern leadership
.
BMJ Leader
vol.
7
,
(
2
)
88
-
90
.
Ramgopal M, Wurapa A, Baumgarten A, Berhe M, Pozniak A, Orkin C, Tiraboschi JM, Hagins DP et al.
(
2022
)
.
1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials
.
Open Forum Infectious Diseases
vol.
9
,
(
Supplement_2
)
Waters L, Winston A, Reeves I, Boffito M, Churchill D, Cromarty B, Dunn D, Fink D et al.
(
2022
)
.
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022
.
HIV Medicine
vol.
23
,
(
S5
)
3
-
115
.
Thornhill J, Orkin C, Cevik M
(
2022
)
.
Estimating the global impact of coronavirus disease 2019 on people living with HIV
.
Current Opinion in Infectious Diseases
vol.
36
,
(
1
)
20
-
25
.
Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, Galliez RM, Garlin AB et al.
(
2022
)
.
Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series
.
The Lancet
vol.
400
,
(
10367
)
1953
-
1965
.
Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe J-J, Marks M, Orkin CM
(
2022
)
.
Monkeypox
.
The Lancet
vol.
401
,
(
10370
)
60
-
74
.
Paparini S, Whitacre R, Smuk M, Thornhill J, Mwendera C, Strachan S, Nutland W, Orkin C
(
2022
)
.
Public understanding and awareness of and response to monkeypox virus outbreak: A cross‐sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency
.
HIV Medicine
vol.
24
,
(
5
)
544
-
557
.
Gibas KM, Kelly SG, Arribas JR, Cahn P, Orkin C, Daar ES, Sax PE, Taiwo BO
(
2022
)
.
Two-drug regimens for HIV treatment
.
The Lancet HIV
vol.
9
,
(
12
)
e868
-
e883
.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F et al.
(
2022
)
.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
.
Clinical Infectious Diseases
vol.
76
,
(
5
)
861
-
870
.
Mocroft A, Geressu A, Beguelin C, Llibre JM, Lazarus JV, Tomazic J, Smidt J, Parczewski M et al.
(
2022
)
.
The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe
.
AIDS
vol.
37
,
(
1
)
91
-
103
.
Mussini C, Guaraldi G, Orkin C
(
2022
)
.
Monkeypox vaccination—an opportunity for HIV prevention
.
The Lancet HIV
vol.
9
,
(
11
)
e741
-
e742
.
Drysdale K, Cutino-Moguel M-T, Dakshina S, Dhairyawan R, Moloney J, Orkin PC, Sarner L, Ullah S et al.
(
2022
)
.
P76 Going, going, gone? Routine emergency department hepatitis C testing can drive elimination efforts. Data from a single UK urban centre show sustained significant decreases in hepatitis C viraemia over time
.
Conference:
Abstractsa89
-
a89
.
Cozzi-Lepri A, Peters L, Pelchen-Matthews A, Neesgaard B, De Wit S, Johansen IS, Edwards S, Stephan C et al.
(
2022
)
.
Observational cohort study of rilpivirine (RPV) utilization in Europe
.
AIDS Research and Therapy
vol.
19
,
(
1
)
Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A et al.
(
2022
)
.
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
.
New England Journal of Medicine
vol.
387
,
(
8
)
679
-
691
.
Boffito M, Scarsi K, Orkin C
(
2022
)
.
Editorial: Is it time to implement injectable antiretroviral treatments globally?
.
Current Opinion in HIV and AIDS
vol.
17
,
(
3
)
119
-
120
.
Orkin C, Cahn P, Castagna A, Emu B, Harrigan PR, Kuritzkes DR, Nelson M, Schapiro J
(
2022
)
.
Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV
.
HIV Medicine
vol.
23
,
(
9
)
936
-
946
.
Wan YI, Apea VJ, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR
(
2022
)
.
Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London
.
Scientific Reports
vol.
12
,
(
1
)
Orkin C, Apea V
(
2022
)
.
International Women's Day—how can I help?
.
The Lancet HIV
vol.
9
,
(
4
)
e228
-
e229
.
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M et al.
(
2022
)
.
A highly virulent variant of HIV-1 circulating in the Netherlands
.
Science
vol.
375
,
(
6580
)
540
-
545
.
Wohl D, Pozniak A, Workowski K, Haggins D, Daar E, Orkin C, Koenig E, Mounzer K et al.
(
2022
)
.
B/F/TAF 5-year outcomes in treatment-naive adults
.
HIV MEDICINE
.
vol.
23
,
29
-
30
.
Daar E, Orkin C, Sax P, Koenig E, Clarke A, Baumgarten A, Brinson C, Huang H et al.
(
2022
)
.
Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomly allocated to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF after 3 years
.
HIV MEDICINE
.
vol.
23
,
12
-
12
.
Paparini S, Strachan S, Thornhill J, Nutland W, Mwendera C, Orkin C
(
2022
)
.
Including women in the public health response to the monkeypox (MPXV) outbreak in the UK: findings from a rapid response, co-produced survey
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
25
,
19
-
19
.
Lathouwers E, Baugh B, Vanveggel S, Van Landuyt E, Opsomer M, Orkin C, Eron J
(
2022
)
.
Long-term efficacy and resistance analyses of D/C/F/TAF in the phase III AMBER and EMERALD studies: post 96-week data
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
25
,
195
-
196
.
Orkin C, Antinori A, Rockstroh J, Guillen SM, Martorell C, Molina J, Lazzarin A, Maggiolo F et al.
(
2022
)
.
Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
25
,
88
-
89
.
Paparini S, Thornhill J, Mwendera C, Strachan S, Whitacre R, Nutland W, Orkin C
(
2022
)
.
Perceptions and understandings of media and public health messaging about the monkeypox outbreak in the UK: findings from a rapid response, co-produced survey
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
25
,
18
-
19
.
Bradshaw D, Abramowicz I, Bremner S, Verma S, Gilleece Y, Kirk S, Nelson M, Housman R et al.
(
2022
)
.
Results of Hepmarc: a 96-week feasibility trial of add-on maraviroc in people with well-controlled HIV and NAFLD
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
25
,
147
-
148
.
Iwuji C, Waters L, Milinkovic A, Orkin C, Perry N, Dailey N, To Y, Bremner S et al.
(
2022
)
.
Switching to bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance: a phase IV randomised, open-label pilot study (PIBIK study)
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
25
,
89
-
90
.
Dhairyawan R, Milner A, Thornhill J, Kwardem L, Matin N, Orkin C, Deane K
(
2022
)
.
The acceptability of offering rapid antiretroviral therapy to people living with HIV in east London: a qualitative study
.
HIV MEDICINE
.
vol.
23
,
13
-
14
.
Thornhill J, Orkin C
(
2021
)
.
Long-acting injectable HIV therapies: the next frontier
.
Current Opinion in Infectious Diseases
vol.
34
,
(
1
)
8
-
15
.
Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink H et al.
(
2021
)
.
HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe
.
HIV Medicine
vol.
23
,
(
6
)
684
-
692
.
Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van Bremen K, Beniowski M, Mikhalik J et al.
(
2021
)
.
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study
.
HIV Medicine
vol.
23
,
(
6
)
585
-
598
.
Campbell L, Ibrahim F, Barbini B, Samarawickrama A, Orkin C, Fox J, Waters L, Gilleece Y et al.
(
2021
)
.
Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir
.
HIV Medicine
vol.
23
,
(
4
)
362
-
370
.
Daar E, Orkin C, Sax P, Stephens JL, Koenig E, Clarke A, Baumgarten A, Brinson C et al.
(
2021
)
.
69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks
.
Open Forum Infectious Diseases
vol.
8
,
(
Supplement_1
)
46
-
46
.
Okhai H, Tariq S, Burns F, Gilleece Y, Dhairyawan R, Hill T, Peters H, Thorne C et al.
(
2021
)
.
Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study
.
The Lancet HIV
vol.
8
,
(
12
)
e747
-
e754
.
Fursa O, Mocroft A, Lazarus JV, Amele S, Lundgren J, Matulionyte R, Rasmussen LD, Rockstroh JK et al.
(
2021
)
.
The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences
.
AIDS
vol.
36
,
(
3
)
423
-
435
.
Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink H-J, Belonosova E, DeMoor R, Griffith S et al.
(
2021
)
.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
.
The Lancet HIV
vol.
8
,
(
11
)
e668
-
e678
.
Lee MJ, Snell LB, Douthwaite ST, Fidler S, Fitzgerald N, Goodwin L, Hamzah L, Kulasegaram R et al.
(
2021
)
.
Clinical outcomes of patients with and without HIV hospitalized with COVID‐19 in England during the early stages of the pandemic: a matched retrospective multi‐centre analysis (RECEDE‐C19 study)
.
HIV Medicine
vol.
23
,
(
2
)
121
-
133
.
Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Wang H, Liu Y et al.
(
2021
)
.
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
88
,
(
4
)
393
-
398
.
Wan YI, Robbins AJ, Apea VJ, Orkin CM, Pearse R, Puthucheary ZA, Prowle JR
(
2021
)
.
Ethnicity and acute hospital admissions: Multi-center analysis of routine hospital data
.
EClinicalMedicine101077
-
101077
.
Wan YI, Apea VJ, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR
(
2021
)
.
Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London
.
medrxiv
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink H-J et al.
(
2021
)
.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
.
Journal of Antimicrobial Chemotherapy
vol.
76
,
(
9
)
2380
-
2393
.
Pelchen-Matthews A, Borges ÁH, Reekie J, Rasmussen LD, Wiese L, Weber J, Pradier C, Degen O et al.
(
2021
)
.
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
87
,
(
2
)
806
-
817
.
Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, Esser S, Huang H et al.
(
2021
)
.
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials
.
Clinical Infectious Diseases
vol.
73
,
(
8
)
1440
-
1451
.
Asad H, Collins I, Goodall R, Crichton S, Hill T, Doerholt K, Foster C, Lyall H et al.
(
2021
)
.
Mortality and AIDS‐defining events among young people following transition from paediatric to adult HIV care in the UK
.
HIV Medicine
vol.
22
,
(
8
)
631
-
640
.
Zenner D
(
2021
)
.
The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London
.
International Journal of Tuberculosis and Lung Disease
Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG et al.
(
2021
)
.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
.
The Lancet HIV
vol.
8
,
(
4
)
e185
-
e196
.
Penfold R, Arnold-Forster A, Orkin C
(
2021
)
.
Redressing Gender Imbalance in Leadership in Academic Medicine
.
Academic Medicine
vol.
96
,
(
4
)
Wan YI, Bien Z, Apea VJ, Orkin CM, Dhairyawan R, Kirwan CJ, Pearse RM, Puthucheary ZA et al.
(
2021
)
.
Acute Kidney Injury in COVID-19: multicentre prospective analysis of registry data
.
Clinical Kidney Journalsfab071-
-
sfab071-
.
Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, d'Arminio Monforte A, Reiss P et al.
(
2021
)
.
Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study
.
Annals of Internal Medicine
vol.
174
,
(
6
)
768
-
776
.
Thornhill J, Orkin C
(
2021
)
.
Long-acting injectable HIV therapies: the next frontier: Republication
.
Current Opinion in HIV and AIDS
vol.
16
,
(
2
)
98
-
105
.
Apea VJ, Wan YI, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR
(
2021
)
.
Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study
.
BMJ Open
vol.
11
,
(
1
)
e042140
-
e042140
.
Cevik M, Haque SA, Manne-Goehler J, Kuppalli K, Sax PE, Majumder MS, Orkin C
(
2021
)
.
Gender disparities in coronavirus disease 2019 clinical trial leadership
.
Clinical Microbiology and Infection
vol.
27
,
(
7
)
1007
-
1010
.
Workowski K, Orkin C, Sax P, Hagins D, Koenig E, Stephens J, Gupta S, Huang H et al.
(
2021
)
.
Four year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive adults
.
HIV MEDICINE
.
vol.
22
,
32
-
33
.
El Bouzidi K, Tostevin A, Pozniak A, Asboe D, Churchill D, Phillips A, Orkin C, Winston A et al.
(
2021
)
.
Integrase inhibitor drug resistance in clinical practice in the United Kingdom
.
HIV MEDICINE
.
vol.
22
,
6
-
6
.
Orkin C, Oka S, Philibert P
(
2021
)
.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study (vol 8, pg e185, 2021)
.
LANCET HIV
vol.
8
,
(
12
)
E734
-
E734
.
Pozniak A, Maggiolo F, Podzamczer D, Yazdanpanah Y, Gupta S, Esser S, Mounzer K, Grossberg R et al.
(
2021
)
.
Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF
.
HIV MEDICINE
.
vol.
22
,
125
-
125
.
Pett S, McCabe L, Latifoltojar A, Post F, Fox J, Burns J, Pool E, Waters A et al.
(
2021
)
.
Results of MAVMET, a multi-centre, open-label, 48-week randomised controlled trial of maraviroc with or without metformin for the treatment of non-alcoholic fatty liver disease in HIV-positive virologically suppressed adults
.
HIV MEDICINE
.
vol.
22
,
43
-
45
.
D'Amico R, Orkin C, Bernal Morell E, Tan DHS, Katner H, Singh Y, Stellbrink H-J, Belonosova E et al.
(
2021
)
.
Safety and efficacy of cabotegravir plus rilpivirine long acting with and without oral lead-in: FLAIR week 124 results
.
INFECTION
.
vol.
49
,
S7
-
S7
.
Molina JM, Orkin C, Cahn P, Lombaard J, Supparatpinyo K, Campbell H, Wan H, Teal V et al.
(
2021
)
.
Safety and efficacy of doravirine in treatment-naive adults with HIV-1: 4 years of experience from the DRIVE-FORWARD and DRIVE-AHEAD clinical trials
.
HIV MEDICINE
.
vol.
22
,
29
-
30
.
Patel P, D'Amico R, Thiagarajah S, Wu S, Elliot E, Polli JW, Upadhyay O, Van Solingen-Ristea R et al.
(
2021
)
.
WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS
.
SEXUAL HEALTH
.
vol.
18
,
VI
-
VI
.
Orkin C, D'Amico R, Bernal Morell E, Tan DHS, Katner H, Singh Y, Stellbrink H-J, Belonosova E et al.
(
2021
)
.
Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection (ITT-E population)
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
24
,
22
-
22
.
Orkin C, Squires KE, Molina J-M, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ et al.
(
2020
)
.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
.
Clinical Infectious Diseases
vol.
73
,
(
1
)
33
-
42
.
Nelson M, Winston A, Hill A, Mngqibisa R, Bassa A, Orkin C, Rassool M, Rodgers A et al.
(
2020
)
.
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine
.
AIDS
vol.
35
,
(
5
)
759
-
767
.
Orkin C, Elion R, Thompson M, Rockstroh JK, Bognar FA, Xu ZJ, Hwang C, Sklar P et al.
(
2020
)
.
Changes in weight and BMI with first-line doravirine-based therapy
.
AIDS
vol.
35
,
(
1
)
91
-
99
.
Mariot P, Orkin C, Elion R, Thompson M, Rockstroh J, Xu Z, Martin E, Hwang C et al.
(
2020
)
.
Effet de la doravirine sur le poids et l’indice de masse corporelle chez les adultes VIH-1 débutant un traitement antirétroviral
.
Infectious Diseases Now
vol.
50
,
(
6
)
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Hernández-Mora MG, Pokrovsky V, Girard P-M et al.
(
2020
)
.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
85
,
(
4
)
498
-
506
.
Garvey L, Cooke G, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al.
(
2020
)
.
AS039 Decline in HCV incidence in HIV positive MSM - progress to HCV micro-elimination in the UK?
.
Journal of Hepatology
vol.
73
,
s32
-
s33
.
Gonzalez-Cordon A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F et al.
(
2020
)
.
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease
.
Journal of Antimicrobial Chemotherapy
vol.
75
,
(
11
)
3334
-
3343
.
Ibrahim F, Campbell L, Bailey A, Stockwell S, Waters L, Orkin C, Johnson M, Gompels M et al.
(
2020
)
.
Estimated glomerular filtration rate slopes on tenofovir alafenamide
.
HIV Medicine
vol.
21
,
(
9
)
607
-
612
.
Iwuji CC, Churchill D, Bremner S, Perry N, To Y, Lambert D, Bruce C, Waters L et al.
(
2020
)
.
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
.
BMC Infectious Diseases
vol.
20
,
(
1
)
van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al.
(
2020
)
.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
85
,
(
3
)
325
-
330
.
Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al.
(
2020
)
.
Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
.
Hepatology
vol.
72
,
(
1
)
7
-
18
.
Apea V, Wan Y, Dhairyawan R, Puthucheary Z, Pearse R, Orkin C, Prowle J
(
2020
)
.
Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study
.
medrxiv
Cevik M, Orkin C, Sax PE
(
2020
)
.
Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
.
Open Forum Infectious Diseases
vol.
7
,
(
6
)
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink H-J et al.
(
2020
)
.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
.
The Lancet HIV
vol.
7
,
(
6
)
e389
-
e400
.
Wan Y, Apea V, Dhairyawan R, Orkin C, Pearse RM, Prowle JR
(
2020
)
.
ETHICAL: Ethnic Disparities In COVID-19 Admissions in east London
.
Orkin C, Goddard SL
(
2020
)
.
Enrolling pregnant women with HIV into clinical trials
.
The Lancet HIV
vol.
7
,
(
5
)
e302
-
e303
.
Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al.
(
2020
)
.
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
.
AIDS
vol.
34
,
(
5
)
707
-
718
.
Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al.
(
2020
)
.
Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?
.
Clinical Infectious Diseases
vol.
72
,
(
2
)
233
-
238
.
Gupta N, Gilleece Y, Orkin C
(
2020
)
.
Implementing U=U in clinical practice: results of a British HIV association members survey
.
Sexually Transmitted Infections
vol.
97
,
(
8
)
619
-
620
.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S et al.
(
2020
)
.
Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection
.
New England Journal of Medicine
vol.
382
,
(
12
)
1124
-
1135
.
Stirrup O, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie N, Tostevin A, Hill T et al.
(
2020
)
.
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation
.
HIV Medicine
vol.
21
,
(
5
)
309
-
321
.
Orkin C, Molina J-M, Yazdanpanah Y, Anania CC, DeJesus E, Eron J, Klopfer S, Grandhi A et al.
(
2020
)
.
Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 infection
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
23
,
15
-
16
.
Orkin C, Molina J, Yazdanpanah Y, Chahin Anania C, DeJesus E, Eron J, Klopfer S, Grandhi A et al.
(
2020
)
.
Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
23
,
51
-
52
.
Garvey L, Cooke G, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al.
(
2020
)
.
Decline in HCV incidence in HIV positive MSM - progress to HCV micro-elimination in the UK?
.
JOURNAL OF HEPATOLOGY
.
vol.
73
,
S32
-
S33
.
Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Liu YP, Wei X et al.
(
2020
)
.
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide versus comparators in cis-women and girls (living with HIV): an analysis of five clinical trials
.
HIV MEDICINE
.
vol.
21
,
18
-
19
.
Parry S, Williamson M, Orkin C, Matin N, Dhairyawan R
(
2020
)
.
HIV-related admissions to a London specialist unit: who, what and why?
.
HIV MEDICINE
.
vol.
21
,
54
-
54
.
Bradshaw D, Abramowicz I, Bremner S, Gilleece Y, Fedele S, Kirk S, Clarke C, Williams S et al.
(
2020
)
.
Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background therapy (OBT) versus OBT alone
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
23
,
76
-
77
.
Samarawickrama A, Hamzah L, Ibrahim F, Ainsworth J, Fox J, Gilleece Y, Hemat N, Johnson M et al.
(
2020
)
.
Increase in bone mineral density and weight in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG
.
HIV MEDICINE
.
vol.
21
,
13
-
13
.
Orkin C, Oka S, Philibert P, Brinson C, Bassa AC, Gusev D, Degen O, Gonzalez Garcia J et al.
(
2020
)
.
Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
.
HIV MEDICINE
.
vol.
21
,
14
-
14
.
Orkin C, Sax P, Arribas J, Gupta S, Martorell C, Stephens J, Stellbrink H-J, DeJesus E et al.
(
2020
)
.
Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
.
HIV MEDICINE
.
vol.
21
,
18
-
18
.
Orkin C
(
2020
)
.
Novel ART compounds
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
23
,
10
-
10
.
D'Amico R, Orkin C, Bernal Morell E, Tan D, Katner H, Singh Y, Stellbrink H, Belonosova E et al.
(
2020
)
.
Safety and efficacy of cabotegravir plus rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
23
,
10
-
12
.
Chounta V, Wu S, Upadhyay O, Griffith S, Harrington C, Orkin C, Swindells S, Spreen W et al.
(
2020
)
.
Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
23
,
24
-
24
.
Andreatta K, Acosta R, D'Antoni M, Porter D, Chang S, Martin R, Willkom M, McNicholl I et al.
(
2020
)
.
Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide
.
HIV MEDICINE
.
vol.
21
,
18
-
18
.
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al.
(
2019
)
.
Impact of early antiretroviral treatment on sexual behaviour
.
AIDS
vol.
33
,
(
15
)
2337
-
2350
.
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al.
(
2019
)
.
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
.
AIDS
vol.
33
,
(
15
)
2337
-
2350
.
(
2019
)
.
Erratum
.
Clinical Infectious Diseases
vol.
70
,
(
2
)
360
-
360
.
Cevik M, Orkin C
(
2019
)
.
Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents
.
Expert Opinion on Investigational Drugs
vol.
28
,
(
12
)
1021
-
1024
.
(
2019
)
.
EACS 2019 – Abstract Book
.
HIV Medicine
.
vol.
20
,
3
-
316
.
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT et al.
(
2019
)
.
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
.
Journal of Virus Eradication
vol.
5
,
(
4
)
204
-
211
.
Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, Peters L, Roen A, Svedhem V, Clarke A et al.
(
2019
)
.
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe
.
AIDS
vol.
33
,
(
13
)
2013
-
2024
.
Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E et al.
(
2019
)
.
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
.
AIDS Research and Human Retroviruses
vol.
36
,
(
1
)
48
-
57
.
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK et al.
(
2019
)
.
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
.
Clinical Infectious Diseases
vol.
71
,
(
6
)
1379
-
1389
.
Huhn GD, Eron JJ, Girard P-M, Orkin C, Molina J-M, DeJesus E, Petrovic R, Luo D et al.
(
2019
)
.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
.
AIDS Research and Therapy
vol.
16
,
(
1
)
Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al.
(
2019
)
.
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
.
The Lancet HIV
vol.
6
,
(
9
)
e576
-
e587
.
Bundle N, Balasegaram S, Parry S, Ullah S, Harris RJ, Ahmad K, Foster GR, Tong CYW et al.
(
2019
)
.
Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016
.
Eurosurveillance
vol.
24
,
(
27
)
Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V et al.
(
2019
)
.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
.
Antiviral Research
vol.
170
,
Orkin C
(
2019
)
.
Does less equal more yet?
.
The Lancet HIV
vol.
6
,
(
7
)
e412
-
e413
.
Thompson M, Orkin C, Molina J-M, Sax P, Cahn P, Squires K, Xu X, Rodgers A et al.
(
2019
)
.
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis
.
Clinical Infectious Diseases
vol.
70
,
(
7
)
1336
-
1343
.
Orkin C, Molina J-M, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G et al.
(
2019
)
.
Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis
.
Clinical Infectious Diseases
vol.
70
,
(
7
)
1344
-
1352
.
Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, Sax PE, Stellbrink H-J et al.
(
2019
)
.
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
.
AIDS
vol.
33
,
(
9
)
1455
-
1465
.
Cullen L, Grenfell P, Rodger A, Orkin C, Mandal S, Rhodes T
(
2019
)
.
‘Just another vial…’: a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK
.
BMJ Open
vol.
9
,
(
4
)
Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, Mallolas J, Zhou Y et al.
(
2019
)
.
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
81
,
(
4
)
463
-
472
.
Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al.
(
2019
)
.
THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection
.
Journal of Hepatology
.
vol.
70
,
Martin EA, Hwang C, Orkin C
(
2019
)
.
Reply to Lanzafame et al
.
Clinical Infectious Diseases
vol.
69
,
(
10
)
1832
-
1833
.
Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard J et al.
(
2019
)
.
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA
.
HIV Medicine
vol.
20
,
(
4
)
264
-
273
.
Finnerty F, Azad Y, Orkin C
(
2019
)
.
Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services
.
The Lancet HIV
vol.
6
,
(
2
)
Gossez M, Martin GE, Pace M, Ramjee G, Premraj A, Kaleebu P, Rees H, Inshaw J et al.
(
2019
)
.
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
.
AIDS
vol.
33
,
(
2
)
185
-
197
.
Podzamczer D, Stellbrink H-J, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al.
(
2019
)
.
B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results
.
HIV MEDICINE
.
vol.
20
,
18
-
18
.
Van Wyk J, Orkin C, Rubio-Garcia R, Bogner J, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al.
(
2019
)
.
Durable suppression and low rate of virological failures 3 years after switch to DTG plus RPV two-drug regimen: SWORD 1 and 2 studies
.
HIV MEDICINE
.
vol.
20
,
18
-
19
.
Orkin C, Elion R, Thompson M, Rockstroh J, Xu ZJ, Martin EA, Hwang C, Sklar P et al.
(
2019
)
.
Effect of doravirine on body weight and body mass index in treatment naive adults with HIV-1
.
HIV MEDICINE
.
vol.
20
,
7
-
8
.
Orkin C, Kityo C, Koenig E, Natukunda E, Ajana F, Gandhi-Patel B, Liu Y, Wei L et al.
(
2019
)
.
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials
.
HIV MEDICINE
.
vol.
20
,
22
-
22
.
Orkin C, Arasteh K, Hernandez-Mora MG, Pokrovsky V, Overton ET, Girard P-M, Oka S, D'Amico R et al.
(
2019
)
.
Long-active cabotegravir plus rilpivirine for HIV maintenance: FLAIR week-48 results
.
HIV MEDICINE
.
vol.
20
,
6
-
7
.
Orkin C, Sax PE, Arribas J, Gupta S, Martorell C, Stephens JL, Stellbrink H-J, Dejesus E et al.
(
2019
)
.
Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
.
HIV MEDICINE
.
vol.
20
,
94
-
95
.
Stellbrink H-J, Post FA, Podzamczer D, Arribas J, Cua E, Molina J-M, Orkin C, Rockstroh JK et al.
(
2019
)
.
Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older
.
HIV MEDICINE
.
vol.
20
,
138
-
138
.
Orkin C, Porteiro N, Berhe M, Dretler R, Viciana P, Tseng Y, Oprea C, Johnson M et al.
(
2019
)
.
Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
.
Journal of Infection and Public Health
.
vol.
12
,
Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C et al.
(
2018
)
.
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
.
Journal of Antimicrobial Chemotherapy
vol.
74
,
(
3
)
746
-
753
.
Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS et al.
(
2018
)
.
Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction
.
Clinical Infectious Diseases
vol.
69
,
(
7
)
1136
-
1143
.
Eron J, Orkin C, Cunningham D, Pulido F, Post F, De Wit S, Lathouwers E, Hufkens V et al.
(
2018
)
.
1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial
.
Open Forum Infectious Diseases
vol.
5
,
(
suppl_1
)
s65
-
s65
.
Rockstroh JK, Bhagani SR, Orkin C, Soto-Malave R, Lacombe K, Zhang Z, Wang S, Mensa F et al.
(
2018
)
.
1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials
.
Open Forum Infectious Diseases
vol.
5
,
(
suppl_1
)
s569
-
s570
.
Thompson M, Orkin C, Molina J-M, Gatell J, Sax P, Cahn P, Squires K, Zhou Y et al.
(
2018
)
.
543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
.
Open Forum Infectious Diseases
vol.
5
,
(
suppl_1
)
s201
-
s202
.
Orkin C, Squires K, Molina J-M, Sax P, Wong W, Sussmann O, Lin G, Kumar S et al.
(
2018
)
.
LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
.
Open Forum Infectious Diseases
vol.
5
,
(
suppl_1
)
s759
-
s759
.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung C-C, Rockstroh JK et al.
(
2018
)
.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
.
The Lancet
vol.
393
,
(
10167
)
143
-
155
.
Orkin C, Squires KE, Molina J-M, Sax PE, Wong W-W, Sussmann O, Kaplan R, Lupinacci L et al.
(
2018
)
.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
.
Clinical Infectious Diseases
vol.
68
,
(
4
)
535
-
544
.
Hagins D, Orkin C, Daar E, Mills A, Brinson C, DeJesus E, Post F, Morales‐Ramirez J et al.
(
2018
)
.
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
.
HIV Medicine
vol.
19
,
(
10
)
724
-
733
.
Vazquez ME, Rockstroh J, Lacombe K, Orkin C, Luetkemeyer A, Wyles D, Malave RS, Shermanl KE et al.
(
2018
)
.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study
.
International Journal of Infectious Diseases
vol.
73
,
Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA et al.
(
2018
)
.
Chronic Kidney Disease Risk in African and Caribbean Populations With HIV
.
The Journal of Infectious Diseases
vol.
218
,
(
11
)
1767
-
1772
.
Eron JJ, Orkin C, Gallant J, Molina J-M, Negredo E, Antinori A, Mills A, Reynes J et al.
(
2018
)
.
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
.
AIDS
vol.
32
,
(
11
)
1431
-
1442
.
Cevik M, Orkin C
(
2018
)
.
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate
.
Current Opinion in HIV and AIDS
vol.
13
,
(
4
)
315
-
319
.
Psomas C, Kinloch S, Sabin C, Soriano V, Solas C, Orkin C, Bernardino J, Curran A et al.
(
2018
)
.
Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16–18 May 2018, Marseille, France: from HIV and comorbidities to global health
.
Journal of Virus Eradication
vol.
4
,
(
3
)
196
-
207
.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E et al.
(
2018
)
.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study
.
Clinical Infectious Diseases
vol.
68
,
(
4
)
597
-
606
.
Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K, Sabin CA, Committee CSS et al.
(
2018
)
.
A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study
.
The Lancet HIV
vol.
5
,
(
6
)
e301
-
e308
.
Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL et al.
(
2018
)
.
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
.
Journal of Viral Hepatitis
vol.
25
,
(
10
)
1180
-
1188
.
Cresswell F, Ellis J, Hartley J, Sabin C, Orkin C, Churchill
(
2018
)
.
A systematic review of risk of HIV transmission through biting or spitting: implications for policy
.
HIV Medicine
vol.
19
,
(
8
)
532
-
540
.
Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C
(
2018
)
.
Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department – uncovering the iceberg?
.
Epidemiology and Infection
vol.
146
,
(
8
)
1026
-
1035
.
Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C et al.
(
2018
)
.
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data
.
AIDS Research and Therapy
vol.
15
,
(
1
)
Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R et al.
(
2018
)
.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
.
Clinical Infectious Diseases
vol.
67
,
(
7
)
1010
-
1017
.
Volz EM, Le Vu S, Ratmann O, Tostevin A, Dunn D, Orkin C, O’Shea S, Delpech V et al.
(
2018
)
.
Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control
.
The Journal of Infectious Diseases
vol.
217
,
(
10
)
1522
-
1529
.
Santos, Cozzi‐Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A et al.
(
2018
)
.
Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe
.
HIV Medicine
vol.
19
,
(
5
)
324
-
338
.
Cresswell F, Ellis J, Hartley J, Sabin C, Brook G, Orkin C, Churchill D
(
2018
)
.
A systematic review of risk of HIV transmission through biting or spitting: implications for policy
.
HIV MEDICINE
.
vol.
19
,
S43
-
S43
.
Podzamczer D, Stellbrink H, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al.
(
2018
)
.
B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 count in two Phase III randomized, controlled clinical trials: Week 96 results
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
21
,
Orkin C, Eron J, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al.
(
2018
)
.
Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
21
,
Krutikov M, Parry S, Drury L, Matin N, Orkin C
(
2018
)
.
HIV-related medical admissions to an HIV specialist inpatient unit: quality standards and outcomes
.
HIV MEDICINE
.
vol.
19
,
S102
-
S103
.
Orkin C, Lampe F, Izambert C, Waters L
(
2018
)
.
Mental health and HIV: what we all need to know
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
21
,
Orkin C, Libre J, Kahl L, Blair E, Wynne B, Curtis L, Angelis K, Shah R et al.
(
2018
)
.
Renal, Inflammatory and bone biomarkers following switch to the DTG + RPV 2-drug regimen: the SWORD-1 and SWORD-2 studies
.
HIV MEDICINE
.
vol.
19
,
S17
-
S17
.
Orkin C, Khuong-Josses M-A, Lutz T, Baker D, Rubio R, Blair E, Kahl L, Angelis K et al.
(
2018
)
.
Safety and efficacy of DTG plus RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location
.
HIV MEDICINE
.
vol.
19
,
S28
-
S29
.
Martinello M, Cerrone M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K et al.
(
2018
)
.
TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection
.
HIV MEDICINE
.
vol.
19
,
S151
-
S152
.
Orkin C, Molina J-M, Gallant J, Negredo E, Gathe J, Eron J, van Landuyt E, Lathouwers E et al.
(
2018
)
.
Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
.
HIV MEDICINE
.
vol.
19
,
S32
-
S32
.
Gallant J, Orkin C, Molina J-M, Negredo E, Antinori A, Mills A, Eron J, Reynes J et al.
(
2018
)
.
Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
.
HIV MEDICINE
.
vol.
19
,
S32
-
S32
.
Roen A, Laut K, Pelchen‐Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, Monforte AD et al.
(
2017
)
.
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort
.
HIV Medicine
vol.
19
,
(
4
)
252
-
260
.
Orkin C, Molina J-M, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E et al.
(
2017
)
.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
.
The Lancet HIV
vol.
5
,
(
1
)
e23
-
e34
.
Cozzi‐Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H et al.
(
2017
)
.
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
.
HIV Medicine
vol.
19
,
(
2
)
102
-
117
.
Orkin C, Molina J-M, Gallant J, Negredo E, Gathe J, Eron J, Van Landuyt E, Lathouwers E et al.
(
2017
)
.
Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults
.
Open Forum Infectious Diseases
vol.
4
,
(
suppl_1
)
s737
-
s738
.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard P-M, Brar I et al.
(
2017
)
.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
.
The Lancet
vol.
390
,
(
10107
)
2063
-
2072
.
Shepherd L, Borges Á, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al.
(
2017
)
.
The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people
.
HIV Medicine
vol.
19
,
(
2
)
90
-
101
.
Gourlay A, Fox J, Gafos M, Fidler S, Nwokolo N, Clarke A, Gilson R, Orkin C et al.
(
2017
)
.
A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England
.
BMJ Open
vol.
7
,
(
8
)
Orkin C, Llibre J, Gallien S, Antinori A, Behrens G, Carr A
(
2017
)
.
Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence
.
HIV Medicine
vol.
19
,
(
1
)
18
-
32
.
Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR et al.
(
2017
)
.
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
.
Open Forum Infectious Diseases
vol.
4
,
(
3
)
Pasvol TJ, Orkin C
(
2017
)
.
Few men who have sex with men (MSM) attending two inner-city clinics were tested for hepatitis C virus (HCV) despite high risk: a retrospective analysis of sexual health screening in East London
.
Sexually Transmitted Infections
vol.
93
,
(
5
)
Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A et al.
(
2017
)
.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
.
The Lancet HIV
vol.
4
,
(
12
)
e536
-
e546
.
Peters L, Mocroft A, Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K et al.
(
2017
)
.
Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study
.
Antiviral Therapy
vol.
23
,
(
5
)
405
-
413
.
Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J et al.
(
2017
)
.
Brief Report
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
.
vol.
75
,
226
-
231
.
O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A et al.
(
2017
)
.
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study
.
The Lancet HIV
vol.
4
,
(
7
)
e295
-
e302
.
Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell A et al.
(
2017
)
.
A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada
.
HIV Medicine
vol.
18
,
(
9
)
655
-
666
.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin C et al.
(
2017
)
.
An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs
.
Journal of Antimicrobial Chemotherapy
vol.
72
,
(
7
)
2075
-
2082
.
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B et al.
(
2017
)
.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
.
The Lancet HIV
vol.
4
,
(
5
)
e195
-
e204
.
Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink H-J, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al.
(
2017
)
.
Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort
.
Clinical Infectious Diseases
vol.
64
,
(
10
)
1413
-
1421
.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard P-M, Brar I et al.
(
2017
)
.
A Phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at Week 48
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
20
,
103
-
104
.
Rockstroh J, Lacombe K, Viani R, Orkin C, Wyles D, Luetkemeyer A, Soto-Malave R, Flisiak R et al.
(
2017
)
.
Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
20
,
13
-
13
.
Molina J-M, Gallant J, Orkin C, Negredo E, Bhatti L, Gathe J, Van Landuyt E, Lathouwers E et al.
(
2017
)
.
Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
20
,
28
-
28
.
Squires KE, Molina J-M, Sax PE, Wong W-W, Orkin C, Sussmann O, Tutu D, Lupinacci L et al.
(
2017
)
.
Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naive adults with HIV-1 infection: Week 48 results of the Phase 3 DRIVE-AHEAD study
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
20
,
110
-
+
.
Rockstroh J, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer A, Soto-Malave R, Flisiak R et al.
(
2017
)
.
LBP-522 Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study
.
Journal of Hepatology
vol.
66
,
(
1
)
s102
-
s103
.
Orkin C
(
2017
)
.
Protease inhibitors in anti-retroviral therapy: past, present and future
.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
.
vol.
50
,
S14
-
S14
.
McNulty M, Orkin C, Smith C, Marshall N, Swaden L, Burns F
(
2017
)
.
Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT)
.
HIV MEDICINE
.
vol.
18
,
17
-
18
.
Parry S, Ullah S, Foster G, Ahmad K, Tong W, Orkin C, Balasegaram S, Bundle N et al.
(
2017
)
.
Routine blood-borne virus testing for HIV, hepatitis B and hepatitis C in the emergency department: the 'new normal'?
.
HIV MEDICINE
.
vol.
18
,
5
-
6
.
Martinello M, Bhagani S, Gane EJ, Orkin C, Cooke G, Kulasegaram R, Shaw D, Hellard M et al.
(
2017
)
.
Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study
.
HEPATOLOGY
.
vol.
66
,
574A
-
575A
.
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al.
(
2017
)
.
Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
.
HIV MEDICINE
.
vol.
18
,
21
-
21
.
Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnson M, Beeching NJ et al.
(
2016
)
.
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy
.
AIDS
vol.
30
,
(
17
)
2617
-
2624
.
Fauci A, Hill A, Bekker L, Montaner J, Lundgren J, Rojo P, Laut KG, Shepherd L et al.
(
2016
)
.
International Congress of Drug Therapy in HIV Infection 23‐26 October 2016, Glasgow, UK
.
Journal of the International AIDS Society
vol.
19
,
(
8Suppl 7
)
Dhairyawan R, O'Connell R, Flanagan S, Wallis E, Orkin C
(
2016
)
.
Linkage to care after routine HIV, hepatitis B & C testing in the emergency department: the ‘Going Viral’ campaign
.
Sexually Transmitted Infections
vol.
92
,
(
7
)
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D et al.
(
2016
)
.
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes
.
Medicine
vol.
95
,
(
41
)
Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K et al.
(
2016
)
.
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression
.
Medicine
vol.
95
,
(
40
)
Bouzidi KE, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A et al.
(
2016
)
.
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
.
Journal of Antimicrobial Chemotherapy
vol.
71
,
(
12
)
3487
-
3494
.
Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S et al.
(
2016
)
.
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015
.
HIV Medicine
vol.
17
,
(
S4
)
s2
-
s104
.
Howarth A, Burns F, Apea V, Jose S, Hill T, Delpech, Evans A, Mercer C et al.
(
2016
)
.
Development and application of a new measure of engagement in out‐patient HIV care
.
HIV Medicine
vol.
18
,
(
4
)
267
-
274
.
Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A et al.
(
2016
)
.
Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom
.
HIV Medicine
vol.
18
,
(
3
)
204
-
213
.
Ericsen A, Lauck M, Mohns M, Dinapoli S, Mutschler J, Greene J, Weinfurter J, Lehrer‐Brey G et al.
(
2016
)
.
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa
.
Journal of the International AIDS Society
vol.
19
,
(
6 Suppl 5
)
Pasvol T, Khan P, Thiagarajan A, Dakshina S, Sarner L, Orkin C
(
2016
)
.
O028 Low proportion of men who have sex with men (MSM) tested for hepatitis C despite high prevalence in 2 genito-urinary medicine (GUM) clinics
.
Sexually Transmitted Infections
vol.
92
,
(
Suppl 1
)
a11.1
-
a1a11
.
Orkin C, Rjinders B, Stephan C, McKellar M, Kiertiburanakul S, Arribas J, Murphy D, Bloch M et al.
(
2016
)
.
P045 Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults
.
Sexually Transmitted Infections
.
vol.
92
,
a34.1
-
a3a34
.
(
2016
)
.
Predicting virological decay in patients starting combination antiretroviral therapy
.
AIDS
vol.
30
,
(
11
)
1817
-
1827
.
Orkin C, Jeffery-Smith A, Foster GR, Tong CYW
(
2016
)
.
Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?
.
BMJ Open
vol.
6
,
(
5
)
e010661
-
e010661
.
White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D et al.
(
2016
)
.
No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom
.
The Journal of Infectious Diseases
vol.
214
,
(
9
)
1302
-
1308
.
Arenas-Pinto A, Stöhr W, Jäger HR, Haddow L, Clarke A, Johnson M, Chen F, Winston A et al.
(
2016
)
.
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial
.
Clinical Infectious Diseases
vol.
63
,
(
2
)
257
-
264
.
Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R et al.
(
2016
)
.
Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the “Going Viral” campaign
.
HIV Medicine
vol.
17
,
(
3
)
222
-
230
.
Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J et al.
(
2016
)
.
Infection‐related and ‐unrelated malignancies, HIV and the aging population
.
HIV Medicine
vol.
17
,
(
8
)
590
-
600
.
Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T et al.
(
2016
)
.
Clinical characteristics and outcomes of HIV-associated immune complex kidney disease
.
Nephrology Dialysis Transplantation
vol.
31
,
(
12
)
2099
-
2107
.
The Antiretroviral Therapy Cohort Collaboration COCC
(
2016
)
.
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada
.
AIDS
vol.
30
,
(
3
)
503
-
513
.
Rodger A, Lampe F, Burman W, Gruhlich A, Friedland G, El-Sadr W, Neaton J, Emery S et al.
(
2016
)
.
Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
19
,
Umaipalan A, Jayakumar A, Patel M, Wallis E, Baily G, Orkin C
(
2016
)
.
Early virological response did not predict high levels of sustained virological response at 12 weeks (SVR12) in HIV/HCV-co-infected patients treated with directly acting agent (DAA)-containing therapy
.
HIV MEDICINE
.
vol.
17
,
45
-
45
.
Stohr W, Dunn D, Arenas-Pinto A, Paton N, Orkin C, Clarke A, Williams I, Johnson M et al.
(
2016
)
.
Factors associated with virological rebound in patients receiving protease inhibitor monotherapy in the PIVOT trial
.
HIV MEDICINE
.
vol.
17
,
11
-
11
.
Barr E, Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G et al.
(
2016
)
.
High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study
.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
.
vol.
31
,
66
-
66
.
Dakshina S, Rieu R, Richards T, Cottrill C, Orkin C
(
2016
)
.
Is there a role for a network-wide Kaposi sarcoma clinic in 2015? A review of transfers and clinical outcomes
.
HIV MEDICINE
.
vol.
17
,
66
-
66
.
Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Yan M, Abram ME et al.
(
2016
)
.
Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
19
,
Marshall N, McNulty M, Smith C, Swaden L, Burns F, Orkin C
(
2016
)
.
Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT)
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
19
,
Umaipalan A, Dakshina S, Khan P, Bunker N, Orkin C
(
2016
)
.
Routine HIV testing in critical care
.
HIV MEDICINE
.
vol.
17
,
56
-
56
.
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al.
(
2016
)
.
Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
19
,
Orkin C, Clarke A, Gallant J, Daar E, Raffi F, Antonucci S, Mingjin Y, Chang A et al.
(
2016
)
.
Switching tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults
.
HIV MEDICINE
.
vol.
17
,
18
-
18
.
Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer A, Lazzarin A, Soto-Malave R, Nelson M et al.
(
2016
)
.
TURQUOISE-I Part 2: safety and efficacy of ombitasvir plus paritaprevir/r ±dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
19
,
Rockstroh J, Orkin C, Viani R, Wyles D, Luetkemeyer A, Lazzarin A, Soto-Malave R, Nelson M et al.
(
2016
)
.
TURQUOISE-I part 2: safety and efficacy of ombitasvir plus paritaprevir/r±dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
19
,
Marwaha S, Dakshina S, Umaipalan A, Pasvol T, Baily G, Orkin C
(
2016
)
.
The transfer times and outcomes of a tertiary in-patient HIV ward
.
HIV MEDICINE
.
vol.
17
,
69
-
69
.
Bath R, O'Connell R, Lascar M, Ferrand R, Strachan S, Matin N, Bassnet I, Orkin C
(
2015
)
.
TestMeEast: a campaign to increase HIV testing in hospitals and to reduce late diagnosis
.
AIDS Care
vol.
28
,
(
5
)
608
-
611
.
Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte AD et al.
(
2015
)
.
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study
.
The Lancet HIV
vol.
3
,
(
1
)
e23
-
e32
.
Orkin C, Wallis E
(
2015
)
.
Should HIV testing week be blood-borne-virus testing week?
.
The Lancet HIV
vol.
2
,
(
12
)
e510
-
e511
.
Huntington S, Thorne C, Newell M-L, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al.
(
2015
)
.
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
.
AIDS
vol.
29
,
(
17
)
2269
-
2278
.
Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M et al.
(
2015
)
.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
.
The Lancet Infectious Diseases
vol.
16
,
(
1
)
43
-
52
.
Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus J, Wentworth D, Johnson M, Vjecha MJ et al.
(
2015
)
.
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
.
PLOS ONE
vol.
10
,
(
10
)
Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, Tong CYW
(
2015
)
.
High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: Should we be screening for HCV in ED attendees?
.
Epidemiology and Infection
vol.
143
,
(
13
)
2837
-
2840
.
Orkin C, Umaipalan A
(
2015
)
.
NtRTI sparing in patients at risk of bone disease
.
The Lancet HIV
vol.
2
,
(
11
)
e452
-
e453
.
Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F et al.
(
2015
)
.
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial
.
The Lancet HIV
vol.
2
,
(
10
)
e417
-
e426
.
Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO, Kellam P et al.
(
2015
)
.
Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals
.
Philosophical Transactions of the Royal Society B Biological Sciences
vol.
370
,
(
1676
)
Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler S, Ainsworth J, Allan S et al.
(
2015
)
.
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation
.
HIV Medicine
vol.
17
,
(
5
)
368
-
372
.
Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Collins S, Fox J, McLean K et al.
(
2015
)
.
The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK
.
PLOS ONE
vol.
10
,
(
7
)
Pate KM, Pohlmeyer C, Walker‐Sperling V, Foote J, Najarro K, Cryer C, Salgado M, Gama L et al.
(
2015
)
.
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada
.
Journal of the International AIDS Society
vol.
18
,
(
5Suppl 4
)
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA et al.
(
2015
)
.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
.
New England Journal of Medicine
vol.
373
,
(
9
)
795
-
807
.
Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM et al.
(
2015
)
.
HIV resistance testing and detected drug resistance in Europe
.
AIDS
vol.
29
,
(
11
)
1379
-
1389
.
Hamlyn E, Stöhr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F et al.
(
2015
)
.
The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels
.
AIDS
vol.
29
,
(
11
)
1355
-
1361
.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS et al.
(
2015
)
.
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
.
The Lancet HIV
vol.
2
,
(
8
)
e319
-
e327
.
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P et al.
(
2015
)
.
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study
.
The Lancet HIV
vol.
2
,
(
8
)
e335
-
e343
.
Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M et al.
(
2015
)
.
Liver-related death among HIV/hepatitis C virus-co-infected individuals
.
AIDS
vol.
29
,
(
10
)
1205
-
1215
.
Williams A, Wallis E, Orkin C
(
2015
)
.
HIV research trials versus standard clinics for antiretroviral-naïve patients: the outcomes differ but do the patients?
.
International Journal of STD & AIDS
vol.
27
,
(
7
)
537
-
542
.
Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA, Database OBOTUHDR, Aitken C et al.
(
2015
)
.
Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom
.
Clinical Infectious Diseases
vol.
61
,
(
5
)
829
-
836
.
Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M et al.
(
2015
)
.
Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study
.
HIV Medicine
vol.
16
,
(
9
)
533
-
543
.
Boesecke C, Grint D, Soriano V, Lundgren JD, Monforte AD, Mitsura VM, Chentsova N, Hadziosmanovic V et al.
(
2015
)
.
Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?
.
Liver International
vol.
35
,
(
11
)
2384
-
2391
.
Lederman M, Bautista‐Arredondo S, Bertozzi S, Sosa‐Rubi S, Gulick R, del Rio C, Beyrer C, Román E et al.
(
2015
)
.
HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico
.
Journal of the International AIDS Society
vol.
18
,
(
3Suppl 2
)
Santana J, Rockstroh J, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B et al.
(
2015
)
.
O322: Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV co-infected patients with HCV GT1-4 infection: the PHOTON-1 and -2 Trials
.
Journal of the International AIDS Society
vol.
18
,
(
3 (Suppl 2)
)
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M et al.
(
2015
)
.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
.
The Lancet
vol.
385
,
(
9987
)
2606
-
2615
.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag M et al.
(
2015
)
.
P0887 : C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV
.
Journal of Hepatology
vol.
62
,
Orkin C, Leach E, Flanagan S, Wallis E, Foster GR, Ruf M, Tong CY
(
2015
)
.
P1247 : Unexpected high prevalence of HCV-viraemia (HCVRNA+) in the emergency department (ED) of a London hospital - should we be screening for HCV in ED attendees?
.
Journal of Hepatology
.
vol.
62
,
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D et al.
(
2015
)
.
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
.
PLOS Medicine
vol.
12
,
(
3
)
Flanagan S, Umaipalan A, Baily G, Orkin C
(
2015
)
.
Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment
.
Journal of AIDS and HIV Research
vol.
7
,
(
3
)
33
-
35
.
Huntington S, Thorne C, Newell M-L, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al.
(
2015
)
.
Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy
.
AIDS
vol.
29
,
(
7
)
801
-
809
.
Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina J-M, Wood R, Neaton JD
(
2015
)
.
Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial
.
HIV Medicine
vol.
16
,
(
S1
)
1
-
9
.
ORKIN C, LEACH E, FLANAGAN S, WALLIS E, RUF M, FOSTER GR, TONG CYW
(
2015
)
.
High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?
.
Epidemiology and Infection
vol.
143
,
(
13
)
2837
-
2840
.
Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R et al.
(
2015
)
.
A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals
.
PLOS ONE
vol.
10
,
(
2
)
Molina J-M, Orkin C, Iser DM, Zamora F-X, Nelson M, Stephan C, Massetto B, Gaggar A et al.
(
2015
)
.
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
.
The Lancet
vol.
385
,
(
9973
)
1098
-
1106
.
Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J et al.
(
2015
)
.
Structured Observations Reveal Slow HIV-1 CTL Escape
.
PLOS Genetics
vol.
11
,
(
2
)
Bath R, Ahmad K, Orkin C
(
2015
)
.
Routine HIV testing within the emergency department of a major trauma centre: a pilot study
.
HIV Medicine
vol.
16
,
(
5
)
326
-
328
.
Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, Hunt SL
(
2015
)
.
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes
.
The Journal of Infectious Diseases
.
vol.
212
,
367
-
377
.
Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R et al.
(
2015
)
.
Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
.
Clinical Infectious Diseases
vol.
60
,
(
8
)
1262
-
1268
.
Deayton J, O'Sullivan E, McKnight A, Groves K, Bibby D, Clark D, Orkin C, Reeves I et al.
(
2015
)
.
Disease progression in HIV-1 controllers; uptake and outcome of antiretroviral therapy
.
HIV MEDICINE
vol.
16
,
20
-
20
.
Raman L, Duschl J, Wallis E, Orkin C
(
2015
)
.
Effectiveness of opt-out HIV testing on a medical assessment unit in a high-prevalence area
.
HIV MEDICINE
.
vol.
16
,
49
-
49
.
Rockstroh JK, Nelson M, Katlama C, Lalezari JP, Mallolas J, Bloch M, Matthews G, Saag M et al.
(
2015
)
.
High Efficacy of Grazoprevir/Elbasvir (GZR/EBR) in HCV Genotype 1, 4, and 6-infected Patients With HIV Coinfection: SVR24 Data From the Phase 3 C-EDGE Coinfection Study
.
HEPATOLOGY
.
vol.
62
,
317A
-
317A
.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag MS et al.
(
2015
)
.
High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4 and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
18
,
Wallis E, Umaipalan A, Flanagan S, Montoto S, Orkin C
(
2015
)
.
Post chemotherapy liver dysfunction and reactivation of Hepatitis B (HBV) and C (HCV) in an HIV-infected cohort
.
HIV MEDICINE
vol.
16
,
41
-
41
.
Borges ÁH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM et al.
(
2014
)
.
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease
.
AIDS
vol.
28
,
(
17
)
2565
-
2571
.
Berkowitz EM, Moyle G, Stellbrink H-J, Schürmann D, Kegg S, Stoll M, Idrissi ME, Oostvogels L et al.
(
2014
)
.
Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
.
The Journal of Infectious Diseases
vol.
211
,
(
8
)
1279
-
1287
.
Mahy M, Nzima M, Ogungbemi MK, Ogbang DA, Morka MC, Stover J
(
2014
)
.
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
.
AIDS
vol.
28
,
(
16
)
2461
-
2473
.
Wallis E, Thornhill J, Saunders J, Orkin C
(
2014
)
.
Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia?
.
Sexually Transmitted Infections
vol.
91
,
(
3
)
Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D et al.
(
2014
)
.
HIV-1 DNA predicts disease progression and post-treatment virological control
.
eLife
vol.
3
,
Flanagan S, Crawford-Jones A, Orkin C
(
2014
)
.
Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection
.
Expert Review of Clinical Pharmacology
vol.
7
,
(
6
)
691
-
704
.
Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A et al.
(
2014
)
.
Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study
.
Clinical Infectious Diseases
vol.
59
,
(
11
)
1579
-
1587
.
Hué S, Brown AE, Ragonnet-Cronin M, Lycett SJ, Dunn DT, Fearnhill E, Dolling DI, Pozniak A et al.
(
2014
)
.
Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions
.
AIDS
vol.
28
,
(
13
)
1967
-
1975
.
Thornhill J, Sivaramakrishnan A, Orkin C
(
2014
)
.
Pneumococcal vaccination in people living with HIV
.
Vaccine
vol.
33
,
(
28
)
3159
-
3160
.
Arenas-Pinto A, Winston A, Stöhr W, Day J, Wiggins R, Quah SP, Ainsworth J, Fleck S et al.
(
2014
)
.
Neurocognitive Function in HIV-Infected Patients: Comparison of Two Methods to Define Impairment
.
PLOS ONE
vol.
9
,
(
7
)
Takebe Y, Naito Y, Raghwani J, Fearnhill E, Sano T, Kusagawa S, Mbisa JL, Zhang H et al.
(
2014
)
.
Intercontinental Dispersal of HIV-1 Subtype B Associated with Transmission among Men Who Have Sex with Men in Japan
.
Journal of Virology
vol.
88
,
(
17
)
9864
-
9876
.
Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD, Committee TIESGASS
(
2014
)
.
Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation
.
Journal of the American Heart Association
vol.
3
,
(
3
)
Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F et al.
(
2014
)
.
Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy
.
AIDS
vol.
28
,
(
9
)
1333
-
1339
.
Hodcroft E, Hadfield JD, Fearnhill E, Phillips A, Dunn D, O'Shea S, Pillay D, Brown AJL et al.
(
2014
)
.
The Contribution of Viral Genotype to Plasma Viral Set-Point in HIV Infection
.
PLOS Pathogens
vol.
10
,
(
5
)
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M et al.
(
2014
)
.
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
.
AIDS
vol.
28
,
(
8
)
1193
-
1202
.
Thornhill J, Mandersloot G, Bath R, Orkin C
(
2014
)
.
Opt-out HIV testing in adult critical care units
.
The Lancet
vol.
383
,
(
9927
)
O’Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M et al.
(
2014
)
.
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression
.
AIDS
vol.
28
,
(
6
)
919
-
924
.
Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M et al.
(
2014
)
.
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression
.
AIDS
vol.
28
,
(
6
)
869
-
874
.
Brown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, Angus BJ, Cameron DW et al.
(
2014
)
.
The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study
.
PLOS ONE
vol.
9
,
(
3
)
Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S et al.
(
2014
)
.
Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis
.
AIDS Patient Care and STDs
vol.
28
,
(
4
)
168
-
175
.
Borges ÁH, O’Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G et al.
(
2014
)
.
Factors Associated with D-Dimer Levels in HIV-Infected Individuals
.
PLOS ONE
vol.
9
,
(
3
)
Coutinho R, Pria AD, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A, Papanastasopoulos P et al.
(
2014
)
.
HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era
.
AIDS
vol.
28
,
(
5
)
689
-
697
.
Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J et al.
(
2014
)
.
HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression
.
AIDS
vol.
28
,
(
5
)
699
-
708
.
Huntington S, Thorne C, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T, Tookey P et al.
(
2014
)
.
Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
.
BMC Infectious Diseases
vol.
14
,
(
1
)
Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J et al.
(
2014
)
.
Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure
.
The Journal of Infectious Diseases
vol.
210
,
(
3
)
363
-
373
.
(
2014
)
.
The increasing genetic diversity of HIV-1 in the UK, 2002–2010
.
AIDS
vol.
28
,
(
5
)
773
-
780
.
Grint D, Peters L, Rockstroh JK, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O et al.
(
2014
)
.
Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis
.
AIDS
vol.
28
,
(
4
)
577
-
587
.
Group W, Bower M, Palfreeman A, Alfa‐Wali M, Bunker C, Burns F, Churchill D, Collins S et al.
(
2014
)
.
British HIV Association guidelines for HIV‐associated malignancies 2014
.
HIV Medicine
vol.
15
,
(
S2
)
1
-
92
.
Shepherd L, Souberbielle J-C, Bastard J-P, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A et al.
(
2014
)
.
Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons
.
The Journal of Infectious Diseases
vol.
210
,
(
2
)
234
-
243
.
Foster GM, Ambrose JC, Hué S, Delpech VC, Fearnhill E, Abecasis AB, Leigh Brown AJ, Geretti AM
(
2014
)
.
Novel HIV-1 Recombinants Spreading across Multiple Risk Groups in the United Kingdom: The Identification and Phylogeography of Circulating Recombinant Form (CRF) 50_A1D
.
PLOS ONE
vol.
9
,
(
1
)
Bath R, O'Connell R, Lascar M, Ferrand R, Matin N, Basnett I, Apea V, Phiri E et al.
(
2014
)
.
#TestMeEast@EuroHIVTestingWeek: a celebrity-endorsed, newsworthy NHS campaign across six hospitals to test 2500 patients (500/day) based in outpatients (OPD) and emergency departments (ED): the results
.
HIV MEDICINE
.
vol.
15
,
95
-
95
.
Wikeley S, Bradbury R, Bath R, O'Connell R, Matin N, Saunders J, Lascar M, Phiri E et al.
(
2014
)
.
'Legion' of medical students participates in largest hospital-based HIV testing week initiative - breaking down testing barriers in the doctors of tomorrow
.
HIV MEDICINE
.
vol.
15
,
91
-
91
.
Thornhill J, Mandersloot G, Bath R, Orkin C
(
2014
)
.
Erratum: Opt-out HIV testing in adult critical care units (Lancet (2014) 383 (1460))
.
The Lancet
vol.
383
,
(
9930
)
Krupiczojc M, Goldsmith P, Cerio R, Orkin C, Williams E, Harwood C
(
2014
)
.
Noduloulcerative skin lesions in an HIV-positive man: an increasingly common presentation of an ancient disease
.
BRITISH JOURNAL OF DERMATOLOGY
.
vol.
171
,
101
-
102
.
Thornhill J, Mandersloot G, Bath R, Orkin C
(
2014
)
.
Opt-out HIV testing in adult critical care units (vol 383, pg 1460, 2014)
.
LANCET
vol.
383
,
(
9930
)
1720
-
1720
.
Wilkins E, Moyle G, Orkin C, Fisher M, Johnson M, Arribas J, Van Lunzen J, Garner W et al.
(
2014
)
.
STaR study: Single-tablet regimen (STR) of Rilpivirine/Emtricitabine/Tenofovir DF demonstrates significant difference to Efavirenz/Emtricitabine/Tenofovir DF in subjects with a baseline HIV-1 RNA ≤ 100,000 copies/mL through week 96
.
HIV MEDICINE
.
vol.
15
,
115
-
116
.
Rockstroh JK, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B, Svarovskaia ES et al.
(
2014
)
.
Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials
.
HEPATOLOGY
.
vol.
60
,
295A
-
296A
.
Keikawus A, Murray D, Junhai G, Jean-Michel L, Chloe O, Ann-Marie Q, Douglas WP
(
2014
)
.
TRANxITION 144 Week Results: Switching Virologically Stable HIV Patients from Immediate-release Nevirapine (NVP IR) to Extended-Release NVP (XR)
.
Journal of AIDS & Clinical Research
vol.
05
,
(
04
)
Orkin C, Wohl DA, Williams A, Deckx H
(
2014
)
.
Vitamin D deficiency in HIV: a shadow on long-term management?
.
Aids Reviews
vol.
16
,
(
2
)
59
-
74
.
Orkin C, Clumeck N, Girard P-M, Henry K, Gathe J, Rockstroh J, DeJesus E, Yau S et al.
(
2014
)
.
Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir boosted by Ritonavir plus Emtricitabine/Tenofovir DF at week 144 in treatment-naive HIV-1-infected patients
.
HIV MEDICINE
.
vol.
15
,
114
-
114
.
Group W, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K et al.
(
2013
)
.
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)
.
HIV Medicine
vol.
15
,
(
S1
)
1
-
6
.
Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y et al.
(
2013
)
.
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz
.
Journal of Antimicrobial Chemotherapy
vol.
69
,
(
4
)
1090
-
1097
.
Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C et al.
(
2013
)
.
The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations
.
HIV Medicine
vol.
15
,
(
5
)
311
-
316
.
Group W, Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G et al.
(
2013
)
.
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013
.
HIV Medicine
vol.
14
,
(
S4
)
1
-
71
.
(
2013
)
.
HLA B*5701 status, disease progression, and response to antiretroviral therapy
.
AIDS
vol.
27
,
(
16
)
2587
-
2592
.
Boffito M, Fox J, Bowman C, Fisher M, Orkin C, Wilkins E, Jackson A, Pleguezuelos O et al.
(
2013
)
.
Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial
.
Vaccine
vol.
31
,
(
48
)
5680
-
5686
.
Moyle GJ, Stellbrink H-J, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H et al.
(
2013
)
.
96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study
.
Antiviral Therapy
vol.
18
,
(
7
)
905
-
913
.
Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F et al.
(
2013
)
.
Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure
.
PLOS ONE
vol.
8
,
(
9
)
Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C et al.
(
2013
)
.
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults
.
AIDS
vol.
27
,
(
14
)
2245
-
2253
.
Molina J, Clumeck N, Orkin C, Rimsky, Vanveggel S, Stevens M, Groups EATS
(
2013
)
.
Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials
.
HIV Medicine
vol.
15
,
(
1
)
57
-
62
.
Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT, Resistance FTUCGOHD et al.
(
2013
)
.
Persistence of HIV-1 Transmitted Drug Resistance Mutations
.
The Journal of Infectious Diseases
vol.
208
,
(
9
)
1459
-
1463
.
Grint D, Peters L, Schwarze‐Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V et al.
(
2013
)
.
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
.
HIV Medicine
vol.
14
,
(
10
)
614
-
623
.
Wallis E, Saunders J, Orkin C
(
2013
)
.
P2.042 An Audit of HIV Testing Rates in Patients Admitted with Pneumonia Pre- and Post- Implementation of Opt-Out HIV Testing For Acute Medical Admissions
.
Sexually Transmitted Infections
vol.
89
,
(
Suppl 1
)
Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA et al.
(
2013
)
.
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study
.
Journal of Antimicrobial Chemotherapy
vol.
68
,
(
10
)
2339
-
2343
.
Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A et al.
(
2013
)
.
Stability of hepatitis C virus (HCV) RNA levels among interferon‐naïve HIV/HCV‐coinfected individuals treated with combination antiretroviral therapy
.
HIV Medicine
vol.
14
,
(
6
)
370
-
378
.
Cohen CJ, Molina J-M, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink H-J et al.
(
2013
)
.
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
.
AIDS
vol.
27
,
(
6
)
939
-
950
.
Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B et al.
(
2013
)
.
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring
.
Journal of Antimicrobial Chemotherapy
vol.
68
,
(
6
)
1354
-
1359
.
Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C et al.
(
2013
)
.
Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study
.
PLOS ONE
vol.
8
,
(
2
)
Koning FA, Castro H, Dunn D, Tilston P, Cane PA, Mbisa JL, Resistance OBOTUCGOHD
(
2013
)
.
Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors
.
Journal of Antimicrobial Chemotherapy
vol.
68
,
(
6
)
1220
-
1236
.
Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H et al.
(
2013
)
.
Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo)
.
Antiviral Therapy
vol.
19
,
(
2
)
191
-
200
.
Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D et al.
(
2013
)
.
Second-Line Protease Inhibitor-Based Antiretroviral Therapy after Non-Nucleoside Reverse Transcriptase Inhibitor Failure: The Effect of a Nucleoside Backbone
.
Antiviral Therapy
vol.
18
,
(
2
)
213
-
219
.
Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R
(
2013
)
.
Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection
.
AIDS
vol.
27
,
(
3
)
313
-
323
.
Brown S, Simpson DM, Moyle G, Brew BJ, Schifitto G, Larbalestier N, Orkin C, Fisher M et al.
(
2013
)
.
NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials
.
AIDS Research and Therapy
vol.
10
,
(
1
)
Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN et al.
(
2013
)
.
Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters
.
Retrovirology
vol.
10
,
(
1
)
Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M et al.
(
2013
)
.
Short-Course Antiretroviral Therapy in Primary HIV Infection
.
New England Journal of Medicine
vol.
368
,
(
3
)
207
-
217
.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A et al.
(
2013
)
.
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe
.
The Journal of Infectious Diseases
vol.
207
,
(
8
)
1216
-
1220
.
Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D et al.
(
2013
)
.
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
.
The Lancet
vol.
381
,
(
9868
)
735
-
743
.
Huntington SE, Thorne C, Bansi LK, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T et al.
(
2013
)
.
Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care
.
AIDS
vol.
27
,
(
1
)
95
-
103
.
Thornhill J, Wallis E, Cho S, Khan P, Sivaramakrishnan A, Amin A, Orkin C
(
2013
)
.
Cross-sectional analysis of invasive pneumococcal disease in a London HIV-positive cohort
.
HIV MEDICINE
.
vol.
14
,
67
-
67
.
Coutinho R, Flook M, Pria A, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A et al.
(
2013
)
.
HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA
.
HAEMATOLOGICA
.
vol.
98
,
129
-
129
.
Hartley A, Annesley C, Davies K, Orkin C, Williams A
(
2013
)
.
In an ageing HIV positive cohort with mixed gender and sexuality, is bone mineral density impaired?
.
HIV MEDICINE
.
vol.
14
,
23
-
23
.
Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N et al.
(
2013
)
.
Neurocognitive function in HIV infected patients on antiretroviral therapy
.
PLoS One
vol.
8
,
(
4
)
Zolopa A, Rockstroh J, Orkin C, Stellbrink H-J, Walmsley S, Cooper D, Zhong L, Fordyce M et al.
(
2013
)
.
Ninety-six-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF - subgroup analyses by baseline HIV-1 RNA and CD4 cells
.
PHARMACOTHERAPY
.
vol.
33
,
E210
-
E211
.
Tariq S, Bath R, Tillett S, Nori A, Saunders J, Mandersloot G, Orkin C
(
2013
)
.
Opt-out HIV testing within intensive care in a large urban hospital: an innovative testing initiative
.
HIV MEDICINE
.
vol.
14
,
46
-
46
.
Williams E, Bath R, Vaidh N, Tillett S, Mandersloot G, Poole N, Saunders J, Tariq S et al.
(
2013
)
.
Project 'Test the Hospital'
.
HIV MEDICINE
.
vol.
14
,
47
-
47
.
Cresswell F, Gothard A, Cevik M, Haidari G, Alexander H, Katsarolis I, McGinty T, Wolujewic A et al.
(
2013
)
.
Safety and efficacy of rilpivirine-tenofovir-emtricitabine (Eviplera®) in hepatitis C-HIV coinfection
.
ANTIVIRAL THERAPY
.
vol.
18
,
A61
-
A61
.
Orkin C, Rockstroh J, DeJesus E, Henry K, Molina J, Gathe J, Wei X, Fordyce M et al.
(
2013
)
.
Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients
.
HIV MEDICINE
.
vol.
14
,
56
-
56
.
Groves KC, Bibby DF, Clark DA, Isaksen A, Deayton JR, Anderson J, Orkin C, Stagg AJ et al.
(
2012
)
.
Disease Progression in HIV-1–Infected Viremic Controllers
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
61
,
(
4
)
407
-
416
.
Cohen M, Perno C, El‐Sadr W, Molina J, Saag M, Lundgren J, Mussini C, Reiss P et al.
(
2012
)
.
Eleventh International Congress on Drug Therapy in HIV Infection
.
Journal of the International AIDS Society
vol.
15
,
Molina J, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M
(
2012
)
.
Rilpivirine efficacy, virology and safety in ARV treatment‐naïve patients with viral load≤100,000 HIV‐1 RNA c/mL: ECHO and THRIVE 96‐week results
.
Journal of the International AIDS Society
.
vol.
15
,
1
-
2
.
Arastéh K, Drulak M, Guo J, Livrozet J, Orkin C, Quinson A, Ward D
(
2012
)
.
TRANxITION 144‐week results: switching virologically stable HIV patients from immediate‐release nevirapine (NVP IR) to extended‐release NVP (XR)
.
Journal of the International AIDS Society
.
vol.
15
,
1
-
1
.
Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M et al.
(
2012
)
.
Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study
.
PLOS ONE
vol.
7
,
(
11
)
Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M et al.
(
2012
)
.
Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial
.
HIV Medicine
vol.
14
,
(
1
)
49
-
59
.
Kyrychenko T, Dubynska G, Koval T, Kaidashev I, Korshenko V, Rono K, Kibuuka H, Maganga L et al.
(
2012
)
.
Track B Clinical Science
.
Journal of the International AIDS Society
vol.
15
,
(
Suppl 3
)
18439
-
18401
.
Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J
(
2012
)
.
Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study
.
PLOS ONE
vol.
7
,
(
10
)
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al.
(
2012
)
.
HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
.
Journal of Clinical Oncology
vol.
30
,
(
33
)
4111
-
4116
.
Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF et al.
(
2012
)
.
Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection
.
PLOS ONE
vol.
7
,
(
8
)
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R et al.
(
2012
)
.
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study
.
AIDS
vol.
26
,
(
13
)
1691
-
1705
.
Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL, Churchill D et al.
(
2012
)
.
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study
.
The BMJ
vol.
345
,
(
aug21 2
)
Orkin C, Nelson M, Katlama C, Morlat P, Furrer H, van Delft Y, Janssen M, Hill A et al.
(
2012
)
.
Changes in Patient-reported Neuropsychiatric Outcomes during the SENSE Trial: First-line Treatment with Two Nucleoside Analogues plus Etravirine or Efavirenz
.
Health Outcomes Research in Medicine
vol.
3
,
(
3
)
e113
-
e119
.
Huntington SE, Bansi LK, Thorne C, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T et al.
(
2012
)
.
Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women
.
BMC Medical Research Methodology
vol.
12
,
(
1
)
Group W, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K et al.
(
2012
)
.
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012
.
HIV Medicine
vol.
13
,
(
S2
)
1
-
6
.
Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ et al.
(
2012
)
.
Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy: A Randomized Controlled Trial
.
JAMA
vol.
308
,
(
4
)
353
-
361
.
Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C et al.
(
2012
)
.
Biomarkers to Monitor Safety in People on ART and Risk of Mortality
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
60
,
(
1
)
51
-
58
.
Nelson M, Amaya G, Clumeck N, da Cunha CA, Jayaweera D, Junod P, Li T, Tebas P et al.
(
2012
)
.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
.
Journal of Antimicrobial Chemotherapy
vol.
67
,
(
8
)
2020
-
2028
.
Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S et al.
(
2012
)
.
Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection
.
AIDS
vol.
26
,
(
7
)
887
-
890
.
Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA, Group CHCCS
(
2012
)
.
Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients
.
American Journal of Kidney Diseases
vol.
60
,
(
4
)
539
-
547
.
(
2012
)
.
Uptake and Outcome of Combination Antiretroviral Therapy in Men Who Have Sex with Men According to Ethnic Group
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
.
vol.
59
,
523
-
529
.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I et al.
(
2012
)
.
Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
.
Clinical Infectious Diseases
vol.
54
,
(
9
)
1364
-
1372
.
Castro H, Pillay D, Sabin C, Dunn DT, the UK Collaborative Group on HIV Drug Resistance
(
2012
)
.
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
.
BMC Medical Research Methodology
vol.
12
,
(
1
)
Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D et al.
(
2012
)
.
Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy?
.
The Journal of Infectious Diseases
vol.
205
,
(
4
)
540
-
547
.
Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, Tobias JK, Vanhove GF
(
2012
)
.
A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
59
,
(
2
)
126
-
133
.
Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D et al.
(
2012
)
.
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
.
Journal of Antimicrobial Chemotherapy
vol.
67
,
(
4
)
995
-
1000
.
DeJesus E, Orkin C, Rockstroh J, Molina J-M, White K, Wei X, Plummer A, Kearney B et al.
(
2012
)
.
Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects at 48 weeks
.
HIV MEDICINE
.
vol.
13
,
9
-
9
.
Orkin C, Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M et al.
(
2012
)
.
HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era
.
HIV MEDICINE
vol.
13
,
5
-
5
.
Williams A, Uthayakumar A, De Souza C, Murthen L, Hand J, Apea V, Orkin C
(
2012
)
.
HIV research trials versus standard clinics for antiretroviral (ARV) naive patients: the outcomes differ but do the patients?
.
HIV MEDICINE
.
vol.
13
,
76
-
76
.
Orkin C, Arribas J, Hodder S, Stellbrink HJ, Vanveggel S, Deckx H, Stevens M
(
2012
)
.
Incidence of rash in the 96-week analysis of the pooled Phase III randomised double-blind ECHO and THRIVE trials
.
HIV MEDICINE
.
vol.
13
,
50
-
50
.
Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D et al.
(
2012
)
.
Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086)
.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
.
vol.
15
,
55
-
55
.
Orkin C, Cohen C, Molina J-M, Cassetti I, Chetchotisakd P, Lazzarin A, Rhame F, Stellbrink HJ et al.
(
2012
)
.
Pooled Week 96 efficacy and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV;TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults
.
HIV MEDICINE
.
vol.
13
,
68
-
69
.
Williams A, Goh B, Orkin C
(
2012
)
.
SpR Trek: the next generation
.
HIV MEDICINE
.
vol.
13
,
17
-
17
.
Dhairyawan R, Lowe S, Ncube B, Jones A, Strachen S, Apea V, Orkin C
(
2012
)
.
The first 9 months: the lost to follow up (LTFU) clinic is born. A sustained approach to re-engaging patients
.
HIV MEDICINE
.
vol.
13
,
77
-
77
.
Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y et al.
(
2011
)
.
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial
.
Journal of Antimicrobial Chemotherapy
vol.
67
,
(
3
)
685
-
690
.
Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti A, Kelleher P et al.
(
2011
)
.
British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011
.
HIV Medicine
vol.
13
,
(
1
)
1
-
44
.
Arasteh K, Ward D, Plettenberg A, Livrozet J, Orkin C, Cordes C, Guo J, Wang E et al.
(
2011
)
.
Twenty‐four‐week efficacy and safety of switching virologically suppressed HIV‐1‐infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION)
.
HIV Medicine
vol.
13
,
(
4
)
236
-
244
.
Dhairyawan R, Longwill S, Orkin C, Montoto S
(
2011
)
.
An innovative joint approach to HIV and lymphoma care
.
Sexually Transmitted Infections
vol.
88
,
(
1
)
Dua J, Nori A, Elliot E, Goh B, Orkin C
(
2011
)
.
Blinded by love: Ocular syphilis as the initial manifestation of HIV Category: Clinical lesson
.
Journal of Infection
vol.
63
,
(
6
)
Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA
(
2011
)
.
Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients
.
Nephrology Dialysis Transplantation
vol.
27
,
(
6
)
2291
-
2297
.
Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A et al.
(
2011
)
.
Non‐uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK
.
HIV Medicine
vol.
13
,
(
1
)
73
-
78
.
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al.
(
2011
)
.
HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,
.
Blood
vol.
118
,
(
21
)
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A et al.
(
2011
)
.
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
.
The BMJ
vol.
343
,
(
oct11 2
)
Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G
(
2011
)
.
Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration
.
Journal of Clinical Virology
vol.
52
,
(
4
)
367
-
369
.
Huntington SE, Bansi LK, Thorne C, Anderson J, Newell M-L, Taylor GP, Pillay D, Hill T et al.
(
2011
)
.
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception
.
AIDS
vol.
25
,
(
13
)
1647
-
1655
.
Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T et al.
(
2011
)
.
Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study
.
Antiviral Therapy
vol.
16
,
(
6
)
805
-
814
.
English S, Katzourakis A, Bonsall D, Flanagan P, Duda A, Fidler S, Weber J, McClure M et al.
(
2011
)
.
Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants
.
Retrovirology
vol.
8
,
(
1
)
Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al.
(
2011
)
.
Authors' response to Drs Scourfield, Jackson and Nelson
.
HIV Medicine
vol.
12
,
(
7
)
450
-
451
.
Prosperi MCF, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A et al.
(
2011
)
.
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
.
Journal of Antimicrobial Chemotherapy
vol.
66
,
(
8
)
1886
-
1896
.
Hughes R, Sterne J, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J et al.
(
2011
)
.
Long‐term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study
.
HIV Medicine
vol.
12
,
(
10
)
583
-
593
.
Donegan KL, Walker AS, Dunn D, Judd A, Pillay D, Menson E, Lyall H, Tudor-Williams G et al.
(
2011
)
.
The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk
.
Antiviral Therapy
vol.
17
,
(
4
)
599
-
603
.
Cain LE, Logan R, Robins JM, Sterne JAC, Sabin C, Bansi L, Justice A, Goulet J et al.
(
2011
)
.
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study
.
Annals of Internal Medicine
vol.
154
,
(
8
)
509
-
515
.
Bird SR, Noronha M, Kurowski W, Orkin C, Sinnott H
(
2011
)
.
Integrated Care Facilitation Model Reduces Use of Hospital Resources by Patients with Pediatric Asthma
.
Journal for Healthcare Quality
vol.
34
,
(
3
)
25
-
33
.
Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, Horne R, group FTS
(
2011
)
.
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz
.
AIDS Care
vol.
23
,
(
6
)
705
-
713
.
Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK et al.
(
2011
)
.
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial
.
PLOS ONE
vol.
6
,
(
3
)
Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ et al.
(
2011
)
.
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients
.
AIDS
vol.
25
,
(
5
)
651
-
657
.
Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C et al.
(
2011
)
.
Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease(CME)
.
Neurology
vol.
76
,
(
8
)
693
-
700
.
Lazzarin A, Orkin C, De Jesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, Lathouwers E et al.
(
2011
)
.
ARTEMIS: 192-WEEK EFFICACY AND SAFETY OF ONCE DAILY DARUNAVIR/RITONAVIR (DRV/R) VERSUS LOPINAVIR/R (LPV/R) IN TREATMENT-NAIVE HIV-1-INFECTED ADULTS
.
INFECTION
.
vol.
39
,
S26
-
S27
.
Dhairyawan R, Longwill S, Orkin C, Montoto S
(
2011
)
.
An innovative joint approach to HIV and lymphoma care
.
HIV MEDICINE
vol.
12
,
38
-
38
.
Castagna A, Lazzarin A, Carosi G, Andreoni M, Orkin C, Streinu-Cercel A, Erscoiu S, Nelson M et al.
(
2011
)
.
CHANGES IN PATIENT-REPORTED OUTCOMES DURING THE SENSE TRIAL: FIRST-LINE TREATMENT WITH 2 NRTIS PLUS ETRAVIRINE OR EFAVIRENZ
.
INFECTION
.
vol.
39
,
S64
-
S64
.
Wohl D, Doroana M, Orkin C, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H et al.
(
2011
)
.
Change in vitamin D levels smaller, and risk of development of severe vitamin D deficiency lower, among HIV-1-infected, treatment-naive adults receiving TMC278 compared with efavirenz: 48-week results from the Phase III ECHO trial
.
HIV MEDICINE
.
vol.
12
,
1
-
1
.
Dua J, Nori A, Cottrill C, Orkin C
(
2011
)
.
Cutaneous Kaposi's sarcoma: a case of mistaken identity
.
HIV MEDICINE
.
vol.
12
,
40
-
40
.
Hartley A, Garrett N, Orkin C, Sarner L, Ault N
(
2011
)
.
Does better tolerated antiretroviral therapy (ART) allow us to modernize post-exposure prophylaxis (PEP)
.
HIV MEDICINE
.
vol.
12
,
15
-
16
.
Draeger E, Smith K, Hogan S, Orkin C
(
2011
)
.
Evaluation of a new clinic model: increasing enrolment into clinical trials without increasing staffing or costs
.
HIV MEDICINE
.
vol.
12
,
19
-
20
.
Longwill S, Nori A, Orkin C, O'Connell B, Creighton S, Dorward J, Reeves I
(
2011
)
.
First contact: exploring relationships between HIV clinics, primary care, geography and HIV diagnoses in North East London
.
HIV MEDICINE
.
vol.
12
,
64
-
64
.
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al.
(
2011
)
.
HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era
.
BLOOD
.
vol.
118
,
1557
-
1557
.
Nori A, Jethwa N, Chung E, Orkin C
(
2011
)
.
HIV in the older patient: an overlooked population?
.
HIV MEDICINE
.
vol.
12
,
67
-
67
.
Byrne L, Whitburn T, Vearncombe S, Orkin C, Noble H
(
2011
)
.
HIV specialists must lead the way to make HIV testing truly routine
.
HIV MEDICINE
.
vol.
12
,
64
-
65
.
Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G
(
2011
)
.
Successful treatment of acute hepatitis C virus in a cohort of HIV-positive patients
.
HIV MEDICINE
.
vol.
12
,
43
-
43
.
Moyle G, Orkin C, Fisher M, Taylor S, Ross J, Wang H, Simcock C
(
2011
)
.
Switching to a simplified single-tablet regimen (STR) of Atripla (ATR) from a two- or three-pill combination of the individual components (efavirenz [EFV], emtricitabine [FTC] and tenofovir DF [TDF]) maintains virological suppression: primary endpoint results of a 48-week, open-label study
.
HIV MEDICINE
vol.
12
,
79
-
79
.
Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C et al.
(
2010
)
.
HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era
.
European Journal of Neurology
vol.
18
,
(
3
)
527
-
534
.
Fryer HR, Frater J, Duda A, Roberts MG, Phillips RE, McLean AR
(
2010
)
.
Modelling the Evolution and Spread of HIV Immune Escape Mutants
.
PLOS Pathogens
vol.
6
,
(
11
)
Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, Lathouwers E, Spinosa‐Guzman S
(
2010
)
.
ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment‐naïve HIV‐1‐infected adults
.
Journal of the International AIDS Society
vol.
13
,
(
Suppl 4
)
p3
-
p3
.
Moyle G, Orkin C, Fisher M, Anderson J, Dhar J, Wang M, Ewan J
(
2010
)
.
Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24‐week, randomized study
.
Journal of the International AIDS Society
vol.
13
,
(
Suppl 4
)
p80
-
p80
.
Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al.
(
2010
)
.
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters
.
HIV Medicine
vol.
12
,
(
5
)
289
-
298
.
Stellbrink H-J, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G et al.
(
2010
)
.
Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study
.
Clinical Infectious Diseases
vol.
51
,
(
8
)
963
-
972
.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D et al.
(
2010
)
.
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
.
Antiviral Therapy
vol.
15
,
(
7
)
985
-
991
.
Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S
(
2010
)
.
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK
.
AIDS
vol.
24
,
(
15
)
2397
-
2401
.
Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, Aubin K, Hand J, Isaksen A et al.
(
2010
)
.
Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection
.
Journal of General Virology
vol.
91
,
(
11
)
2794
-
2803
.
Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D
(
2010
)
.
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
.
AIDS
vol.
24
,
(
12
)
1917
-
1922
.
Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A et al.
(
2010
)
.
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study
.
The Lancet
vol.
376
,
(
9738
)
340
-
345
.
Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P et al.
(
2010
)
.
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations*
.
HIV Medicine
vol.
11
,
(
7
)
432
-
438
.
Orkin C, Wang J, Bergin C, Molina J-M, Lazzarin A, Cavassini M, Esser S, Sirvent J-LG et al.
(
2010
)
.
An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe
.
Pharmacogenetics and Genomics
vol.
20
,
(
5
)
307
-
314
.
Group CGOHDRAUCS
(
2010
)
.
Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy
.
Clinical Infectious Diseases
vol.
50
,
(
9
)
1275
-
1285
.
Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M et al.
(
2010
)
.
Data linkage reduces loss to follow-up in an observational HIV cohort study
.
Journal of Clinical Epidemiology
vol.
63
,
(
10
)
1101
-
1109
.
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M et al.
(
2010
)
.
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma
.
AIDS
vol.
24
,
(
6
)
851
-
856
.
Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T et al.
(
2010
)
.
Late diagnosis in the HAART era: proposed common definitions and associations with mortality
.
AIDS
vol.
24
,
(
5
)
723
-
727
.
Tavel JA, Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, Paton N, Wentworth D et al.
(
2010
)
.
Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study
.
PLOS ONE
vol.
5
,
(
2
)
de Oliveira T, Pillay D, Gifford RJ
(
2010
)
.
The HIV-1 Subtype C Epidemic in South America Is Linked to the United Kingdom
.
PLOS ONE
vol.
5
,
(
2
)
Orkin C, Sadiq, Rice L, Jackson F, team OBOTUE
(
2010
)
.
Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)‐B*5701 in HIV‐1‐infected UK subjects
.
HIV Medicine
vol.
11
,
(
3
)
187
-
192
.
Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D et al.
(
2010
)
.
Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals
.
PLOS ONE
vol.
5
,
(
1
)
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R et al.
(
2010
)
.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
.
The Lancet
vol.
375
,
(
9712
)
396
-
407
.
Gilson R, Man S, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K et al.
(
2010
)
.
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study*
.
HIV Medicine
vol.
11
,
(
2
)
152
-
160
.
Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A et al.
(
2010
)
.
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
.
AIDS
vol.
24
,
(
1
)
123
-
137
.
Orkin C, Streinu-Cercel A, Erscoiu S, Nelson M, Hill A, van Delft Y, Marks S
(
2010
)
.
Changes in patient-reported outcomes during the SENSE Trial: first-line treatment with 2 NRTIs plus etravirine or efavirenz
.
ANTIVIRAL THERAPY
.
vol.
15
,
A69
-
A69
.
Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas J, Domingo P, Granier C, Pearce H et al.
(
2010
)
.
Comparison of bone and renal toxicities in the ASSERT study: final 96 week results from a prospective randomized safety trial
.
ANTIVIRAL THERAPY
.
vol.
15
,
A19
-
A19
.
Deayton J, Bibby D, Orkin C, O'Sullivan E, McKnight A, Clark D
(
2010
)
.
Inter-clade dual HIV-1 infection in the UK - an emerging phenomenon
.
Bower M, Montoto S, Cwynarski K, Lumsden AS, Rajab R, Okosun J, Orkin C, Nelson M et al.
(
2010
)
.
Non-germinal centre subtype of AIDS-related diffuse large B-cell lymphomas associated with improved survival
.
HIV MEDICINE
vol.
11
,
13
-
13
.
Waters L, Asboe D, Pozniak A, Bansi L, Orkin C, Smit E, Fearnhill E, Phillips A
(
2010
)
.
Outcomes of second-line ritonavir-boosted protease inhibitor (PI/r)-based ART after failure of a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART
.
HIV MEDICINE
.
vol.
11
,
3
-
4
.
Orkin C, Moyle G, Fisher M, Wang H, Ewan J
(
2010
)
.
Switching from Kivexa [KVX] ABC/3TC+efavirenz [EFV] to Atripla [ATR] (EFV/FTC/TDF) reduces cholesterol in hypercholesterolemic subjects: preliminary results of a 24-week randomized study
.
HIV MEDICINE
vol.
11
,
4
-
4
.
Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, Edwards S, Connolly J et al.
(
2009
)
.
Clinical epidemiology of HIV-associated end-stage renal failure in the UK
.
AIDS
vol.
23
,
(
18
)
2517
-
2521
.
Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B et al.
(
2009
)
.
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?
.
AIDS
vol.
23
,
(
18
)
2507
-
2515
.
Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina J-M, Schechter M, Peeters M et al.
(
2009
)
.
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
.
AIDS
vol.
23
,
(
17
)
2289
-
2300
.
Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al.
(
2009
)
.
Factors influencing lopinavir and atazanavir plasma concentration
.
Journal of Antimicrobial Chemotherapy
vol.
65
,
(
1
)
129
-
137
.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K et al.
(
2009
)
.
Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
52
,
(
3
)
391
-
396
.
Dreja H, O'Sullivan E, Pade C, Aubin K, Isaksen A, D'Souza C, Hand J, Orkin C et al.
(
2009
)
.
P04-35. Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients
.
Retrovirology
vol.
6
,
(
Suppl 3
)
Groves K, Bibby D, Isaksen A, Deayton J, Anderson J, Orkin C, Stagg A, McKnight Á
(
2009
)
.
P16-21. Altered T cell homeostasis and activation in HIV-1 elite suppressors with low CD4+ T-cell counts
.
Retrovirology
vol.
6
,
(
Suppl 3
)
Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A et al.
(
2009
)
.
The prevalence of hepatitis C virus (HCV) infection in HIV‐positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes
.
Journal of Viral Hepatitis
vol.
17
,
(
8
)
569
-
577
.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB et al.
(
2009
)
.
Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection
.
The Journal of Infectious Diseases
.
vol.
200
,
973
-
983
.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T et al.
(
2009
)
.
Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir
.
The Journal of Infectious Diseases
vol.
200
,
(
5
)
710
-
714
.
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS et al.
(
2009
)
.
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy
.
AIDS
vol.
23
,
(
13
)
1689
-
1699
.
Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H et al.
(
2009
)
.
A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
.
vol.
51
,
562
-
568
.
Khachi H, O'Connell R, Ladenheim D, Orkin C
(
2009
)
.
Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection
.
Journal of Antimicrobial Chemotherapy
vol.
64
,
(
4
)
871
-
873
.
Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D et al.
(
2009
)
.
Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy
.
Clinical Infectious Diseases
vol.
48
,
(
9
)
1296
-
1305
.
Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L et al.
(
2009
)
.
CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK
.
Haematologica
vol.
94
,
(
6
)
875
-
880
.
Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D
(
2009
)
.
Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naïve Individuals
.
Journal of Virology
vol.
83
,
(
6
)
2645
-
2654
.
Yeni P, LaMarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill F, Teofilo E et al.
(
2009
)
.
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)*
.
HIV Medicine
vol.
10
,
(
2
)
116
-
124
.
Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M et al.
(
2009
)
.
Interruption of antiretroviral therapy is associated with increased plasma cystatin C
.
AIDS
vol.
23
,
(
1
)
71
-
82
.
Wilson J, Montoto S, Shaw K, Orkin C, Johnson M, Nelson M, Bower M, Cwynarski K
(
2009
)
.
Excellent immunological recovery following the intensive chemotherapy CODOX-M/IVAC, an effective therapy for HIV-associated Burkitt's lymphoma
.
HIV MEDICINE
vol.
10
,
5
-
5
.
Sabin C, Smith C, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C et al.
(
2008
)
.
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy
.
HIV Medicine
vol.
10
,
(
1
)
35
-
43
.
Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M et al.
(
2008
)
.
HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeficiency Virus Infection
.
Journal of Virology
vol.
83
,
(
3
)
1228
-
1239
.
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Johnson M et al.
(
2008
)
.
Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt's Lymphoma (BL)
.
Blood
vol.
112
,
(
11
)
Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH et al.
(
2008
)
.
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
.
AIDS
vol.
22
,
(
17
)
2279
-
2289
.
Couto-Parada X, Lee A, Ushiro-Lumb I, Anderson J, Baily G, Limb S, Noble H, Orkin C et al.
(
2008
)
.
Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification
.
Journal of the International AIDS Society
vol.
11
,
(
Suppl 1
)
Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT
(
2008
)
.
The Impact of Different Definitions on the Estimated Rate of Transmitted HIV Drug Resistance in the United Kingdom
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
.
vol.
49
,
196
-
204
.
Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips AN, Sabin CA et al.
(
2008
)
.
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study
.
AIDS
.
vol.
22
,
1943
-
1950
.
Ladenheim D, Horn O, Werneke U, Phillpot M, Murungi A, Theobald N, Orkin C
(
2008
)
.
Potential health risks of complementary alternative medicines in HIV patients
.
HIV Medicine
vol.
9
,
(
8
)
653
-
659
.
El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD et al.
(
2008
)
.
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
.
Annals of Internal Medicine
vol.
149
,
(
5
)
289
-
299
.
Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al.
(
2008
)
.
Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication
.
Antiviral Therapy
vol.
13
,
(
5
)
675
-
685
.
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Bower M et al.
(
2008
)
.
CODOX-M/IVAC CHEMOTHERAPY IS AN EFFECTIVE THERAPY FOR HIV-ASSOCIATED BURKITT'S LYMPHOMA (BL)
.
HAEMATOLOGICA
.
vol.
93
,
393
-
393
.
Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H et al.
(
2008
)
.
HIV-1 DRUG RESISTANCE IN HIV-1-INFECTED CHILDREN IN THE UNITED KINGDOM FROM 1998 TO 2004
.
The Pediatric Infectious Disease Journal
vol.
27
,
(
5
)
457
-
459
.
Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN
(
2008
)
.
Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up
.
The Journal of Infectious Diseases
vol.
197
,
(
8
)
1145
-
1155
.
Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard P-M, Grund B et al.
(
2008
)
.
Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study
.
The Journal of Infectious Diseases
vol.
197
,
(
8
)
1133
-
1144
.
Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J et al.
(
2008
)
.
Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
47
,
(
2
)
202
-
205
.
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M et al.
(
2008
)
.
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
.
AIDS
vol.
22
,
(
3
)
349
-
356
.
Easterbrook P, Phillips A, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G et al.
(
2008
)
.
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK
.
HIV Medicine
vol.
9
,
(
1
)
47
-
56
.
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Bower M et al.
(
2008
)
.
CODOX-M/IVAC CHEMOTHERAPY IS AN EFFECTIVE THERAPY FOR HIV-ASSOCIATED BURKITT'S ILYMPHOMA (BL)
.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
.
vol.
93
,
393
-
393
.
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Johnson M et al.
(
2008
)
.
Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Assochited Burkitt's Lymphorna (BL)
.
BLOOD
.
vol.
112
,
1235
-
1236
.
Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A et al.
(
2007
)
.
Brief communication: rituximab in HIV-associated multicentric Castleman disease
.
Annals of Internal Medicine
vol.
147
,
(
12
)
836
-
839
.
Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T et al.
(
2007
)
.
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
.
The Lancet
vol.
370
,
(
9603
)
1923
-
1928
.
Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M
(
2007
)
.
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease
.
Blood
vol.
110
,
(
12
)
4132
-
4133
.
(
2007
)
.
HIV Diagnosis at CD4 Count Above 500 Cells/mm3 and Progression to Below 350 Cells/mm3 Without Antiretroviral Therapy
.
JAIDS Journal of Acquired Immune Deficiency Syndromes
vol.
46
,
(
3
)
275
-
278
.
Gupta RK, Loveday C, Kalidindi U, Lechelt M, Skinner C, Orkin C
(
2007
)
.
Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice
.
International Journal of STD & AIDS
vol.
18
,
(
9
)
630
-
632
.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M et al.
(
2007
)
.
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
.
AIDS
vol.
21
,
(
13
)
1717
-
1721
.
Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P et al.
(
2007
)
.
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures
.
AIDS
vol.
21
,
(
11
)
1423
-
1430
.
(
2007
)
.
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom
.
AIDS
vol.
21
,
(
8
)
1035
-
1039
.
Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P et al.
(
2007
)
.
CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997–2003
.
HIV Medicine
vol.
8
,
(
3
)
135
-
141
.
Nolan D, Phillips E, Mallal S
(
2005
)
.
Efavirenz and CYP2B6 Polymorphism: Implications for Drug Toxicity and Resistance
.
Clinical Infectious Diseases
vol.
42
,
(
3
)
408
-
410
.
Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B
(
2005
)
.
Estimating HIV-1 Drug Resistance in Antiretroviral-Treated Individuals in the United Kingdom
.
The Journal of Infectious Diseases
.
vol.
192
,
967
-
973
.
Beggs S, Sewell J, Efron D, Orkin C
(
2005
)
.
Developmental assessment of children: A survey of Australian and New Zealand paediatricians
.
Journal of Paediatrics and Child Health
vol.
41
,
(
8
)
444
-
448
.
Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G et al.
(
2005
)
.
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)
.
Journal of Antimicrobial Chemotherapy
vol.
55
,
(
2
)
246
-
251
.
Stebbing J, Nelson M, Orkin C, Mandalia S, Bower M, Pozniak A, Gazzard B
(
2004
)
.
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)
.
Journal of Antimicrobial Chemotherapy
vol.
53
,
(
3
)
501
-
505
.
Morlese JF, Orkin CM, Abbas R, Burton C, Qazi NA, Nelson MR, Imami N, Gazzard BG
(
2003
)
.
Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection
.
AIDS
vol.
17
,
(
9
)
1411
-
1413
.
Morlese J, Qazi N, Orkin C, Datta D, Abbas R, Gazzard B, Francis N, Moyle G
(
2002
)
.
Both stavudine and zidovudine-based therapy is associated with gluteal subcutaneous adipocyte depletion
.
ANTIVIRAL THERAPY
.
vol.
7
,
L22
-
L22
.
Orkin C, Morlese J, Buckingham A, Gazzard B, Asboe D
(
2000
)
.
Estimation of the prevalence of ΔF508 heterozygosity in HIV infected patients with <i>Pseudomonas aeruginosa</i> pulmonary infection
.
AIDS
.
vol.
14
,
S133
-
S133
.